ÑÇÐÇÓÎÏ·¹ÙÍø-www.yaxin868.com

ɽ¶«ÑÇÐÇÓÎÏ·¹ÙÍø»ú´²ÓÐÏÞ¹«Ë¾Ï³´²¹Ù·½ÍøÕ¾½ñÌìÊÇ£º2025-06-14Çл»³ÇÊÐ[È«¹ú]-ÍøÕ¾µØÍ¼
ÍÆ¼ö²úÆ· :
ÍÆ¼öÐÂÎÅ
¼¼ÊõÎÄÕµ±Ç°Î»ÖÃ:¼¼ÊõÎÄÕÂ>

Ò»ÖÖɸѡ¿¹ÌåµÄ·½·¨

ʱ¼ä:2025-06-13    ×÷Õß: ¹ÜÀíÔ±

רÀûÃû³Æ£ºÒ»ÖÖɸѡ¿¹ÌåµÄ·½·¨
¼¼ÊõÁìÓò£º
±¾·¢Ã÷Éæ¼°Ò»ÖÖɸѡ¿¹ÌåµÄ·½·¨¡£
±³¾°¼¼Êõ£º
½èÖúµ°°×չʾ¼¼ÊõµÄ¸ßͨÁ¿¿¹ÌåɸѡÒѾ­³ÉΪÏÖÔÚ¿¹ÌåÖÆ±¸µÄÖ÷Òª·½·¨Ö®Ò»¡£ ÊɾúÌåչʾ¼¼Êõ¡¢ºËÌÇÌåչʾ¼¼ÊõºÍ½Íĸչʾ¼¼ÊõÒѾ­±»¹ã·ºµÄÓ¦ÓÃÓÚп¹ÌåµÄɸѡºÍ ¿¹ÌåÇ׺ÍÁ¦µÄ¸Ä½ø¡£Õ¹Ê¾µÄ¿¹ÌåÄÜÓëÄ¿µÄ¿¹Ô­½áºÏ´Ó¶ø±»¿ìËٵĴӸ´ÔӵĿ¹ÌåÎÄ¿âÖРɸѡ³öÀ´¡£Í¨³£ÓÃÓÚ¿¹ÌåɸѡµÄ¿¹Ô­ÊÇÒÑÖªµÄ¿ÉÈÜÐÔ´¿»¯¿¹Ô­¡£È»¶øÐí¶à¼²²¡µÄ·Ö×Ó ±ê¼Ç¶¼¶¨Î»ÓÚϸ°ûĤ±íÃæ£¬²¢ÇÒ¾ßÓи´Ôӵķ­ÒëºóÐÞÊΣ¬ÀýÈçÌÇ»ù»¯(Ohtsubo K, Marth JD :Glycosylation in cellular mechanisms of health and disease. Cell 2006£¬ 126(5) :855-867.)¡£ÌÇ»ù»¯¶ªÊ§»áÓ°Ïìµ°°×µÄÕÛµþЧÂʺÍÎȶ¨ÐÔ(Shental-Bechor D£¬ Levy Y :Folding of glycoproteins toward understanding the biophysics of the glycosylation code. Curr Opin Struct Biol 2009£¬19 (5) :524_533¡¤)¡£²¢ÇÒÐí¶à°©Ï¸ °û±íÃæµÄÌÇ»ù»¯¶¼ÓÐÃ÷ÏԱ仯(Kim YJ, Varki A !Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997£¬14(5) 569-576.)¡£¿ÉÊÇͨ¹ýÉúÎ﹤³Ì¼¼Êõ½øÐÐÉú²úºÍ´¿»¯µÄ¿ÉÈÜÐÔ¿¹Ô­Í¨³£»á¶ªÊ§·­Òëºó ÐÞÊΣ¬ÎÞ·¨ÕæÊµ·´Ó³ÌìÈ»¿¹Ô­µÄ¹¹Ïó(Liat Binyamina HBaLMW Cancer therapy with engineered monoclonal antibodies Update on Cancer Therapeutics 2006,1 (2) 147-157. Linenberger ML,Maloney DG,Bernstein ID :Antibody_directed therapies for hematological malignancies. Trends Mol Med 2002,8(2) :69_76.)¡£¶øÇÒÓÐʱ¿¹Ô­ÊÇδ ÖªµÄ·Ö×Ó£¬ÎÞ·¨»ñµÃ´¿»¯µÄ¿¹Ô­¡£Òò´ËÈç¹ûÄÜÒÔÍêÕûϸ°ûΪ¿¹Ô­É¸Ñ¡ÌØÒì½áºÏϸ°û±íÃæ¿¹ Ô­µÄ¿¹Ì壬²ÅÓÐÀûÓÚɸѡµ½Ê¶±ðÌìÈ»¿¹Ô­±íλµÄп¹Ì壬½«¸ü¼ÓÓÐÀûÓÚÁÙ´²µÄÕï¶ÏºÍÖÎÁÆ¡£µ½Ä¿Ç°ÎªÖ¹£¬ÊɾúÌåչʾϵͳºÍ½Íĸչʾϵͳ¶¼Òѱ»Ö¤Ã÷Äܹ»Ö±½ÓÒÔÍêÕûµÄϸ°û ×÷Ϊ¿¹Ô­£¬É¸Ñ¡ÌØÒìʶ±ðϸ°û±íÃæ¿¹Ô­µÄ¿¹Ìå¡£µ«ÊÇÊɾúÌåչʾ¼¼ÊõÓÉÓÚչʾЧÂÊÓÐÏÞ£¬²» ÊÇËùÓеÄÐòÁж¼ÄÜÔÚÊɾúÌåÖлñµÃºÜºÃµÄ±í´ï¡£¶øÇÒÔÚÊɾúÌåÀ©ÔöµÄ¹ý³ÌÖУ¬ÓÉÓÚ²åÈëÆ¬ ¶ÎÐÔÖʵIJ»Í¬£¬¿ÉÄܳÊÏÖ³öÉú³¤²îÒ죬´Ó¶ø¿ÉÄܶªÊ§ÎÄ¿â¶àÑùÐÔ¡£´ËÍ⣬ÊɾúÌåչʾϵͳÄÑ ÒÔչʾ·Ö×ÓÁ¿½Ï´óµÄµ°°×£¬Òò´Ë²»Äܳɹ¦Õ¹Ê¾ÍêÕûµÄIgG¿¹Ìå·Ö×Ó¡£¶ø½Íĸչʾ¼¼ÊõÓÉÓÚ Êܵ½×ª»¯Ð§ÂʵÄÓ°Ï죬ºÜÄѹ¹½¨×ã¹»´óµÄ¿¹ÌåÎĿ⡣ͨ³£ÎÄ¿â´óС< 108¡£Ï¸¾úÔ­ÉúÖÊÌåչʾ¼¼Êõ(APEx) (Harvey BR, Georgiou G, Hayhurst A, Jeong KJ, Iverson BL, Rogers GK Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci USA 2004,101(25) :9193_9198.)ÊÇÒ»ÖÖ¸ßЧµÄϸ¾úչʾ ¼¼Êõ¡£APExչʾ¼¼ÊõÊǽ«µ°°×Öʱí´ï¶¨Î»µ½Ï¸¾úÖÜÖʿռäÖУ¬µ°°×ÖÊͨ¹ýN¶ËÈںϵÄÄÚĤ Ö¬µ°°×NlpAµÄÁù¸ö°±»ùËáÐòÁÐ(CDQSSS)ÒÔ¹²¼Ûõ¥»¯µÄ·½Ê½Ãª¶¨ÔÚÄÚĤÍâ²à£¬»òÕßÊÇͨ¹ý C¶ËÈںϵÄM13ÊɾúÌåÍâ¿Çµ°°×3 (g3p)µÄN¶ËƬ¶Ï궨ÔÚÄÚĤÖУ¬´Ó¶ø½«Ä¿µÄµ°°×չʾµ½ ÖÜÖʿռ䡣Ȼºó¿ÉÒÔͨ¹ýEDTAºÍÈܾúøµÄ×÷Óý«Ï¸¾úµÄÍâĤȥµô£¬´Ó¶ø½«ÄÚĤÉÏ궨µÄµ°°×Öʱ©Â¶³öÀ´¡£±©Â¶µÄ¿¹Ìå¿ÉÒÔºÍÓ«¹â±ê¼ÇµÄ¿¹Ô­½áºÏ´Ó¶øÊ¹Ï¸¾ú»ñµÃÃ÷ÏÔµÄÓ«¹â¡£Í¨¹ý Á÷ʽ·ÖÑ¡¿ÉÒÔ½«ÌØÒì½áºÏ¿¹Ô­µÄϸ¾ú·ÖÑ¡³öÀ´£¬´Ó¶ø»ñµÃÏàÓ¦µÄ¿¹Ìå¡£APExչʾϵͳ¾ßÓÐÐí¶àÓŵã¡£(I)APExչʾϵͳÊÇÒ»ÖÖϸ¾úչʾϵͳ£¬ÈÝÒ×¹¹½¨ ¾Þ´óµÄ¿¹ÌåÎÄ¿â(> IO9)¡£(2)궨·½Ê½¶àÑù£¬¿ÉÒÔÑ¡ÔñC¶Ë»òN¶Ë궨¡£(3)ÓÉÓÚ¿¹ÌåÕ¹ ʾÔÚÄÚĤ±íÃæ£¬¶øÄÚĤ²»º¬ÓÐLPS»òÆäËü¸´ÔӵĶàÌÇÀàµÈÍâĤµÄ³É·Ý£¬±íÃæÏà¶ÔƽÕûÒò´Ë ²»»á¶Ô´ó·Ö×Ó¿¹Ô­Ó뿹ÌåµÄ½áºÏ²úÉú¿Õ¼äÓ°Ïì¡£Òò´Ë£¬APExϵͳչʾµÄ¿¹Ìå¿ÉÓÐЧµÄ½áºÏ ·Ö×ÓÁ¿¸ß´ï240kDaµÄ¿ÉÈÜÐÔ¿¹Ô­¡£(4)¿¹ÌåµÄչʾֻÐèÒª´©¹ýÒ»²ãϸ°ûĤ£¬¶ø²»ÐèÒªÏñ½Í ĸչʾ»òϸ¾úÍâĤչʾϵͳÄÇÑùÒª´©Ô½Ï¸°ûÍâ±Ú£¬ÕâʹµÃ¿¹ÌåµÄչʾ²»»áÊÜ·Ö×ÓÁ¿ºÍ¿Õ¼ä ½á¹¹µÄÏÞÖÆ£¬Õ¹Ê¾Ð§¹û¸üºÃ¡£Òò´Ë£¬APExϵͳÄܹ»³É¹¦µØÕ¹Ê¾ÍêÕûµÄIgG¿¹Ìå(Mazor Y,Van Blarcom ¦³, Mabry R, Iverson BL, Georgiou G :Isolation of engineered, full-length antibodies from libraries expressed in Escherichia coli. Nat Biotechnol 2007, 25(5) :563-565.)¡£²¢ÇÒÍêÕûµÄIgG¿¹Ìå¾ßÓÐÁ½¸ö¿¹Ô­½áºÏλµã£¬¿ÉÒÔ²úÉú¶þ¼Û½áºÏ£¬Õ⽫ ÓÐÀûÓÚɸѡµ¥¼Û½áºÏÇ׺ÍÁ¦½ÏµÍµÄ¿¹Ìå¡£(5)¿ÉÒÔÖ±½ÓÀûÓù㷺ʹÓõÄÊɾúÌåÕ¹Ê¾ÔØÌåÀ´ ½øÐе°°×±í´ï£¬ÕâʹµÃ¿ÉÒÔÖ±½ÓÀûÓÃÐí¶àÊɾúÌåչʾµÄµ¥Á´¿¹ÌåµÄÎÄ¿â×ÊÔ´¡£

·¢Ã÷ÄÚÈÝ
±¾·¢Ã÷µÄÒ»¸öÄ¿µÄÊÇÌṩһÖÖɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ·½·¨¡£±¾·¢Ã÷ËùÌṩµÄɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ °û£»2)½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдý ɸѡµ°°×µÄϸ¾úÔ­ÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔ­ÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ ÓÚËùÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔ­ÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔ µÄÏ໥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔ­ÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ½«ËùÊö½áºÏÎï´Ó·õ ÓýÌåϵÖзÖÀë³öÀ´£»4)´Ó²½Öè3)µÃµ½µÄ½áºÏÎïÖзÖÀëµÃµ½ÓëչʾÓÚÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ÌØÒìÐÔ ½áºÏµÄÄ¿µÄµ°°×»òÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£ÉÏÊöɸѡ·½·¨ÖУ¬ËùÊö´ýɸѡµ°°×¿âΪº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ýɸѡ µ°°×¿â¡£¼´¸Ã·½·¨ÊʺÏÓÚº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ýɸѡµ°°×¿â¡£ÉÏÊöɸѡ·½·¨ÖУ¬´ýɸѡµ°°×¿â¿ÉÒÔÊÇÏÖÓеÄÓÃÓÚÊɾúÌåչʾ¼¼ÊõµÄ¿ÉɸѡµÄµ° °×¿â£¬Ò²¿ÉÒÔÊÇÏÖÓеİüº¬¸ü´óµÄ¿¹Ìå(ÀýÈçÍêÕûµÄIgG)µÄµ°°×¿â¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨ËùÊö·õÓýÌåϵ µÄ PH ֵΪ 5. 0-7. 5£¬¾ßÌåΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0,7. 3,7. 5¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Î¶ÈΪ 30-37¡ãC£¬¾ßÌåΪ30¡ãC»ò37¡ãC £»Ê±¼äΪ0. 5-2Сʱ£¬¾ßÌåΪ0. 5h»òIh»ò2h¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖÐ·Ö Àë³öÀ´µÄ·½·¨°üÀ¨£¬Ê×ÏÈʹÓÃÆ½°åÌÔÑ¡·¨É¸Ñ¡£¬È»ºóʹÓÃÁ÷ʽ·ÖÑ¡·¨·ÖÑ¡¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬Ê¹ÓÃÁ÷ʽ·ÖÑ¡·¨µÄ²½ÖèΪÊ×ÏÈ´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδͬËùÊöÕæºËϸ°ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔ­ÉúÖÊÌ壬ÔÙͨ¹ýÁ÷ʽϸ°ûÒÇɸѡ£¬ÊÕ¼¯Ëù ÊöÕæºËϸ°ûÓëÔ­ÉúÖÊÌå·¢ÉúÌØÒìÐÔ½áºÏµÄ½áºÏÎï¡£ÉÏÊöÁ÷ʽϸ°ûÒÇɸѡ·½·¨ÖУ¬ËùÊö´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδÐγɽáºÏÎïµÄϸ¾úÔ­ ÉúÖÊÌåµÄ·½·¨Îª½«ËùÊö·õÓýµÄÌåϵ300gÀëÐÄ1. 5-3·ÖÖÓºó£¬ÊÕ¼¯³Áµí£¬ÆúÈ¥ÉÏÇå¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖзÖÀë³öÀ´µÄ·½·¨ ÖУ»ÌÔÑ¡·¨ÎªÔÚÆ½°åÉÏÌÔÑ¡¿É½áºÏµÄϸ¾úÔ­ÉúÖÊÌ壬ËüÖ÷ÒªÊÇÒ»ÖÖ¶¨ÐÔµÄɸÑ¡£¬ÊǰÑÄܹ»½á ºÏµÄϸ¾úÔ­ÉúÖÊÌ嶼ɸѡ³öÀ´£¬¶ø²»ÊǸù¾Ý½áºÏÁ¦Ç¿ÈõÀ´½øÐÐɸѡ¡£¶øÁ÷ʽϸ°û·ÖÑ¡¼¼Êõ ÊÇÒ»ÖÖ¾ßÓиßͨÁ¿£¬¶à²ÎÊý¶¨Á¿·ÖÑ¡ÄÜÁ¦µÄ¼¼Êõ£¬ËüÄܹ»¸ù¾ÝÇ׺ÍÁ¦Ç¿Èõ½øÐж¨Á¿µÄɸѡ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊö½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ °ûĤ±íÃæÊÇÓɰüÀ¨Èçϲ½ÖèµÄ·½·¨ÖƱ¸µÃµ½µÄ½«º¬ÓÐËùÊöÄ¿±êµ°°×±àÂë»ùÒòµÄÖØ×éÔØÌå תÈëËùÊöÕæºËϸ°ûÖУ¬µÃµ½ÖØ×éÕæºËϸ°û£¬ÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í ´ï£¬µÃµ½ËùÊö±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»ËùÊöÕæºË±í´ïÔØÌå¿ÉÒÔÊÇÈκοÉÔÚÕæºËϸ°ûĤ±íÃæÕ¹Ê¾µÄÔØÌå¡£ÓÅÑ¡ÊÇ pUHD10-3-display(SEQ ID :6)£¬¸ÃÔØÌåÊǰ´ÕÕÈçÏ·½·¨µÃµ½µÄ½«DNAƬ¶Î²åÈëpUHD10_3 ÔØÌåÖÐËÄ»·Ëص÷¿ØµÄÆô¶¯×ÓÏÂÓεÄEcoR IºÍXba IÖ®¼ä£¬µÃµ½ÖмäÖØ×éÔØÌ壻ÔÙ½«ËùÊöÄ¿ ±êµ°°×µÄ±àÂë»ùÒò²åÈëËùÊöÖмäÖØ×éÔØÌåµÄBgl IIºÍSal Iλµã¼ä£¬µÃµ½ËùÊöÄ¿±êµ°°×µÄ ±àÂë»ùÒòµÄÖØ×éÔØÌ壻ËùÊöDNAƬ¶ÎµÄÐòÁÐÈçÏÂËùʾ£¬ÖƱ¸·½·¨ÎªÒÔÔØÌåpDisplayΪģ°å£¬ÓÃÈçÏÂÒýÎï ¶Ô½øÐÐPCRÀ©ÔöµÃµ½µÄÉÏÓι­Ø­ÎïACGCGAATTCGCCACCATGGAGACAGACACACTCCTGCTÏÂÓι­Ø­ÎïAACTAGTCTAGACTAACGTGGCTTCTTCTGCCAAAGCAT¡£ËùÊöÕæºËϸ°û¿ÉÒÔÊÇCH0¡¢C0Sl¡¢C0S7¡¢293T¡¢HeLa¡¢HCT116µÈ£¬ÓÅÑ¡ÊÇH1299ϸ°ûÖê¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊöÄ¿±êµ°°×µÄ±àÂë»ùÒòÊÇÈËÔ´»¯ µÄ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè2)ÖУ¬½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾ ÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæµÄ·½·¨°üÀ¨Èçϲ½Ö轫´ýɸѡµ°°×µÄ±àÂë»ùÒò²åÈëϸ¾ú±í´ïÔØÌå ÖУ¬µÃµ½±í´ïËùÊö´ýɸѡµ°°×µÄÖØ×éÔØÌ壬½«ËùÊö±í´ï´ýɸѡµ°°×µÄÖØ×éÔØÌåתÈëËÞÖ÷ϸ ¾ú£¬µÃµ½ÖØ×éϸ¾ú£¬ÅàÑøËùÊöÖØ×éϸ¾ú²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬ÔÙÌáÈ¡ÖØ×éϸ¾úµÄÔ­Éú ÖÊÌ壬µÃµ½ËùÊö±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔ­ÉúÖÊÌå¡£ËùÊöµÄϸ¾úÖл¹¿ÉÒÔתÈëÓÃÓÚͨ¹ýÓ«¹âÐźÅɸѡԭÉúÖÊÌåµÄÓ«¹âµ°°×±í´ïÔØÌ壬 ¸ÃÔØÌå¿ÉÒÔÊÇÔÚϸ¾úÖбí´ïÈκÎÑÕɫӫ¹âµ°°×ÖʵÄÔØÌ壬ÓÅѡΪPBAD30-KmR-GFPmut2¡£ËùÊöµÄϸ¾ú¿ÉÒÔÊǸ÷Öִ󳦸˾úÈçDH10B£¬Topl0£¬JM109£¬BL21µÈ£¬ÓÅѡΪ´ó³¦¸Ë ¾ú Jude-IÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè4)ÖУ¬ËùÊö´Ó½áºÏÎïÖзÖÀëµÃµ½Ä¿µÄµ°°×»ò Ä¿µÄµ°°×µÄ±àÂë»ùÒòµÄ·½·¨°üÀ¨Èçϲ½Öè´ÓËùÊö½áºÏÎïÖÐÌáÈ¡ËùÊö±í´ïÄ¿µÄµ°°×µÄÖØ×é ÔØÌ壬½«ÖØ×éÔØÌå½øÐвâÐò£¬µÃµ½ËùÊöÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£Êµ¼ÊÓ¦ÓÃÖУ¬ËùÊöÄ¿±êµ°°×¿ÉΪ¿¹Ô­£¬ËùÊö´ýɸѡµ°°×¿ÉΪ¿¹Ì壻ËùÊö¿¹Ìå¾ßÌå¿É ÎªÌØÒìʶ±ðÈËԴϸ°û±íÃæ¿¹Ô­µÄ¿¹Ìå¡£
±¾·¢Ã÷µÄÁíÒ»¸öÄ¿µÄÊÇÌṩһÖÖʹÓÃÉÏÊö·½·¨¸¨Öú¼ø¶¨µ°°×ÊÇ·ñÓëÄ¿±êµ°°×½á ºÏµÄ·½·¨¡£±¾·¢Ã÷ËùÌṩµÄ¸¨Öú¼ø¶¨µ°°×ÊÇ·ñÓëÄ¿±êµ°°×½áºÏµÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæ ºËϸ°û£»2)½«´ý¼ø¶¨µ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдý ¼ø¶¨µ°°×µÄϸ¾úÔ­ÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔ­ÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ ÓÚËùÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔ­ÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔ µÄÏ໥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔ­ÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ¼ì²â·õÓýµÄÌåϵÖÐ ÊÇ·ñº¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÈôº¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×ÓëËùÊöÄ¿±êµ° °×½áºÏ£¬Èô²»º¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×²»ÓëËùÊöÄ¿±êµ°°×½áºÏ¡£ÉÏÊö¼ø¶¨·½·¨ÖУ¬ËùÊö´ý¼ø¶¨µ°°×¿âΪº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ýɸѡ µ°°×¿â¡£¼´¸Ã·½·¨ÊʺÏÓÚº¬ÓÐÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ´ý¼ø¶¨µ°°×¿â¡£ÉÏÊö¼ø¶¨·½·¨ÖУ¬´ý¼ø¶¨µ°°×¿â¿ÉÒÔÊÇÏÖÓеÄÓÃÓÚÊɾúÌåչʾ¼¼ÊõµÄ¿ÉɸѡµÄµ° °×¿â£¬Ò²¿ÉÒÔÊÇÏÖÓеİüº¬¸ü´óµÄ¿¹Ìå(ÀýÈçÍêÕûµÄIgG)µÄµ°°×¿â¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨ËùÊö·õÓýÌåϵ µÄ PH ֵΪ 5. 0-7. 5£¬¾ßÌåΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0,7. 3,7. 5¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Î¶ÈΪ30-37¡ãC ºÍʱ¼äΪ0. 5-2Сʱ¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬¼ì²â·õÓýµÄÌåϵÖÐÊÇ·ñº¬ÓÐËùÊöÌØÒì ÐÔ½áºÏÎïµÄ·½·¨ÊÇÁ÷ʽϸ°ûÒǼì²â¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬ËùÊö²½Öè3)ÖУ¬¿É½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖзÖÀë ³öÀ´ÔÙ½øÐмì²â£¬·ÖÀë·½·¨°üÀ¨£¬Ê×ÏÈʹÓÃÆ½°åÌÔÑ¡·¨É¸Ñ¡£¬È»ºóʹÓÃÁ÷ʽ·ÖÑ¡·¨·ÖÑ¡¡£ÉÏÊöÈÎÒ»ËùÊö¼ø¶¨·½·¨ÖУ¬Ê¹ÓÃÁ÷ʽ·ÖÑ¡·¨µÄ²½ÖèΪÊ×ÏÈ´ÓËùÊö·õÓýÌåϵÖÐÈ¥ ³ýδͬËùÊöÕæºËϸ°ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔ­ÉúÖÊÌ壬ÔÙͨ¹ýÁ÷ʽϸ°ûÒÇɸÑ¡£¬ÊÕ¼¯Ëù ÊöÕæºËϸ°ûÓëÔ­ÉúÖÊÌå·¢ÉúÌØÒìÐÔ½áºÏµÄ½áºÏÎï¡£ÉÏÊöÁ÷ʽϸ°ûÒÇɸѡ·½·¨ÖУ¬ËùÊö´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδÐγɽáºÏÎïµÄϸ¾úÔ­ ÉúÖÊÌåµÄ·½·¨Îª½«ËùÊö·õÓýµÄÌåϵ300gÀëÐÄ1. 5-3·ÖÖÓºó£¬ÊÕ¼¯³Áµí£¬ÆúÈ¥ÉÏÇå¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö½«ËùÊö½áºÏÎï´Ó·õÓýµÄÌåϵÖзÖÀë³öÀ´µÄ·½·¨ ÖУ»ÌÔÑ¡·¨ÎªÔÚÆ½°åÉÏÌÔÑ¡¿É½áºÏµÄϸ¾úÔ­ÉúÖÊÌ壬ËüÖ÷ÒªÊÇÒ»ÖÖ¶¨ÐÔµÄɸÑ¡£¬ÊǰÑÄܹ»½á ºÏµÄϸ¾úÔ­ÉúÖÊÌ嶼ɸѡ³öÀ´£¬¶ø²»ÊǸù¾Ý½áºÏÁ¦Ç¿ÈõÀ´½øÐÐɸѡ¡£¶øÁ÷ʽϸ°û·ÖÑ¡¼¼Êõ ÊÇÒ»ÖÖ¾ßÓиßͨÁ¿£¬¶à²ÎÊý¶¨Á¿·ÖÑ¡ÄÜÁ¦µÄ¼¼Êõ£¬ËüÄܹ»¸ù¾ÝÇ׺ÍÁ¦Ç¿Èõ½øÐж¨Á¿µÄɸѡ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊö½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ °ûĤ±íÃæÊÇÓɰüÀ¨Èçϲ½ÖèµÄ·½·¨ÖƱ¸µÃµ½µÄ½«º¬ÓÐËùÊöÄ¿±êµ°°×±àÂë»ùÒòµÄÖØ×éÔØÌå תÈëËùÊöÕæºËϸ°ûÖУ¬µÃµ½ÖØ×éÕæºËϸ°û£¬ÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í ´ï£¬µÃµ½ËùÊö±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»ËùÊöÕæºË±í´ïÔØÌå¿ÉÒÔÊÇÈκοÉÔÚÕæºËϸ°ûĤ±íÃæÕ¹Ê¾µÄÔØÌå¡£ÓÅÑ¡ÊÇ pUHD10-3-display(SEQ ID :6)£¬¸ÃÔØÌåÊǰ´ÕÕÈçÏ·½·¨µÃµ½µÄ½«DNAƬ¶Î²åÈëpUHD10_3ÔØÌåÖÐËÄ»·Ëص÷¿ØµÄÆô¶¯×ÓÏÂÓεÄEcoR IºÍXba IÖ®¼ä£¬µÃµ½ÖмäÖØ×éÔØÌ壻ÔÙ½«ËùÊöÄ¿ ±êµ°°×µÄ±àÂë»ùÒò²åÈëËùÊöÖмäÖØ×éÔØÌåµÄBgl IIºÍSal Iλµã¼ä£¬µÃµ½ËùÊöÄ¿±êµ°°×µÄ ±àÂë»ùÒòµÄÖØ×éÔØÌ壻ËùÊöDNAƬ¶ÎµÄÐòÁÐÈçÏÂËùʾ£¬ÖƱ¸·½·¨ÎªÒÔÔØÌåpDisplayΪģ°å£¬ÓÃÈçÏÂÒýÎï ¶Ô½øÐÐPCRÀ©ÔöµÃµ½µÄÉÏÓι­Ø­ÎïACGCGAATTCGCCACCATGGAGACAGACACACTCCTGCTÏÂÓι­Ø­ÎïAACTAGTCTAGACTAACGTGGCTTCTTCTGCCAAAGCAT¡£ËùÊöÕæºËϸ°û¿ÉÒÔÊÇCH0¡¢C0Sl¡¢C0S7¡¢293T¡¢HeLa¡¢HCT116µÈ£¬ÓÅÑ¡ÊÇH1299ϸ°ûÖê¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè1)ÖУ¬ËùÊöÄ¿±êµ°°×µÄ±àÂë»ùÒòÊÇÈËÔ´»¯ µÄ¡£ÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè2)ÖУ¬½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾ ÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæµÄ·½·¨°üÀ¨Èçϲ½Ö轫´ýɸѡµ°°×µÄ±àÂë»ùÒò²åÈëϸ¾ú±í´ïÔØÌå ÖУ¬µÃµ½±í´ïËùÊö´ýɸѡµ°°×µÄÖØ×éÔØÌ壬½«ËùÊö±í´ï´ýɸѡµ°°×µÄÖØ×éÔØÌåתÈëËÞÖ÷ϸ ¾ú£¬µÃµ½ÖØ×éϸ¾ú£¬ÅàÑøËùÊöÖØ×éϸ¾ú²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬ÔÙÌáÈ¡ÖØ×éϸ¾úµÄÔ­Éú ÖÊÌ壬µÃµ½ËùÊö±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔ­ÉúÖÊÌå¡£ËùÊöµÄϸ¾úÖл¹¿ÉÒÔתÈëÓÃÓÚͨ¹ýÓ«¹âÐźÅɸѡԭÉúÖÊÌåµÄÓ«¹âµ°°×±í´ïÔØÌ壬 ¸ÃÔØÌå¿ÉÒÔÊÇÔÚϸ¾úÖбí´ïÈκÎÑÕɫӫ¹âµ°°×ÖʵÄÔØÌ壬ÓÅѡΪPBAD30-KmR-GFPmut2¡£ËùÊöµÄϸ¾ú¿ÉÒÔÊǸ÷Öִ󳦸˾úÈçDH10B£¬Topl0£¬JM109£¬BL21µÈ£¬ÓÅѡΪ´ó³¦¸Ë ¾ú Jude-I ¦ÏÉÏÊöÈÎÒ»ËùÊöɸѡ·½·¨ÖУ¬ËùÊö²½Öè4)ÖУ¬ËùÊö´Ó½áºÏÎïÖзÖÀëµÃµ½Ä¿µÄµ°°×»ò Ä¿µÄµ°°×µÄ±àÂë»ùÒòµÄ·½·¨°üÀ¨Èçϲ½Öè´ÓËùÊö½áºÏÎïÖÐÌáÈ¡ËùÊö±í´ïÄ¿µÄµ°°×µÄÖØ×é ÔØÌ壬½«ÖØ×éÔØÌå½øÐвâÐò£¬µÃµ½ËùÊöÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£Êµ¼ÊÓ¦ÓÃÖУ¬ËùÊöÄ¿±êµ°°×¿ÉΪ¿¹Ô­£¬ËùÊö´ý¼ø¶¨µ°°×¿ÉΪ¿¹Ì壻ËùÊö¿¹Ìå¾ßÌå¿É ÎªÌØÒìʶ±ðÈËԴϸ°û±íÃæ¿¹Ô­µÄ¿¹Ìå¡£±¾·¢Ã÷µÄÁíÒ»¸öÄ¿µÄÊÇÌṩһÖÖÓÃÓÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄÊÔ¼ÁºÐ¡£±¾·¢Ã÷ËùÌṩµÄÓÃÓÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄÊÔ¼ÁºÐ£¬ÓÉÕæºËϸ°û¡¢Õæ ºËϸ°û±í´ïÔØÌå¡¢ÓÃÓÚÖÆ±¸Ô­ÉúÖÊÌåµÄϸ¾ú¡¢Ô­ÉúÖÊÌåÕ¹Ê¾ÔØÌå¡¢ÔÚÔ­ÉúÖÊÌåÖбí´ïÓ«¹âµ° °×ÒÔ±ãÓÚɸѡµÄÔØÌå×é³É¡£ÉÏÊöÊÔ¼ÁºÐÖУ¬ËùÊöÀëÌåÈËԴϸ°ûΪÈË·ÇСϸ°û·Î°©Ï¸°ûÖêH1299 £»ËùÊöÕæºËϸ °û±í´ïÔØÌåΪpUHD10-3-display(SEQ ID 6)£»ËùÊöϸ¾úΪ´ó³¦¸Ë¾ú¾úÖêJude-I £»ËùÊö±í´ï Ó«¹âµ°°×µÄÔØÌåΪpBAD30-KmR-GFPmut2¡£Ï¸¾úÔ­ÉúÖÊÌåչʾ·½·¨ÔÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×ÖеÄÓ¦ÓÃÒ²ÊôÓÚ±¾·¢ Ã÷µÄ±£»¤·¶Î§¡£±¾·¢Ã÷ÌṩÁËÀûÓÃAPExչʾ¼¼ÊõÓ¦ÓÃÓÚÒÔÍêÕûµÄÈËϸ°ûΪ¿¹Ô­É¸Ñ¡ÌØÒìʶ±ðÈË Ï¸°û±íÃæ¿¹Ô­µÄ¿¹ÌåµÄÒ»ÖÖɸѡ·½·¨¡£APExϸ¾úչʾϵͳӵÓÐÓëÊɾúÌåչʾϵͳÏ൱´óС µÄ¿¹Ìå¿â(áêIO9)£¬²¢ÇÒ¾ßÓÐչʾÍêÕûµÄIgG¿¹ÌåµÄÄÜÁ¦¡£´ËÍâAPExϸ¾úչʾϵͳ¿ÉÒÔÖ± ½ÓÀûÓù㷺ʹÓõÄÊɾúÌå±í´ïÔØÌå½øÐе°°×չʾ£¬Òò´Ë¿ÉÒÔÖ±½ÓÀûÓÃÏÖÓеÄÊɾúÌåµ¥Á´¿¹ ÌåÎÄ¿â½øÐÐɸѡ¡£´Ë·½·¨µÄ½¨Á¢£¬ÓÐÖúÓÚɸѡ¸ü¶àʶ±ðϸ°û±íÃæ·Ö×Ó±ê¼ÇµÄ¿¹Ì壬¶Ô¼²²¡Õï
8¶ÏºÍÖÎÁƶ¼½«Æðµ½¾Þ´óµÄÍÆ¶¯×÷Óá£


ͼ1Ϊӫ¹âÏÔ΢¾µ¹Û²ìºÍÁ÷ʽϸ°ûÒÇ·ÖÎöH1299_tet on-PAD4ϸ°û±íÃæPAD4µÄ±í´ï¡£Í¼2Ϊӫ¹âÏÔ΢¾µ¹Û²ìϸ¾úÔ­ÉúÖÊÌåÓëÌù±Úϸ°ûµÄ½áºÏ¡£Í¼3ΪH1299_tet on-PAD4ϸ°ûÓëչʾ¿¹ÌåM18µÄϸ¾úÔ­ÉúÖÊÌåµÄÌØÒì½áºÏ¡£Í¼4ΪpHÖµ¶Ôչʾ¿¹ÌåM18µÄϸ¾úÔ­ÉúÖÊÌåÓëH1299_tet on_PAD4ϸ°û½áºÏµÄÓ°Ï졣ͼ5ΪչʾM18¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌåÔÚ²»Í¬³õʼ´¿¶Èʱ±»Æ½°åÌÔÑ¡ºÍÁ÷ʽ·ÖÑ¡µÄ
¸»¼¯Ð§ÂÊ¡£Í¼6Ϊ¶àÂÖ¸»¼¯Õ¹Ê¾M18¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌå¡£
¾ßÌåʵʩÀý·½Ê½±¾·¢Ã÷ÓÃÒÑÓеĿ¹Ô­-¿¹Ìå¶Ô×÷ΪģÐÍ£¬Ö¤Ã÷չʾÁËÌØ¶¨¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌ壬 Äܹ»Í¨¹ýÓëÈËϸ°û±íÃæÕ¹Ê¾µÄ¿¹Ô­Ï໥×÷ÓôӶø½áºÏµ½Ï¸°û±íÃæ¡£Ñ¡ÓÃÁËÌ¿¾Ò¸Ë¾ú±£»¤ ¿¹Ô­µÄÒ»¸öƬ¶ÏPA domaiM×÷Ϊ¿¹Ô­£¬¶ø¶ÔÓ¦µÄµ¥Á´¿¹ÌåΪM18 ScFv0¶ø¿¹µØ¸ßÐÁ±êÇ© (DIG)µÄµ¥Á´¿¹Ìå26-10 scFv×÷ΪÒõÐÔ¶ÔÕÕ¡£½«ÓÕµ¼ºóµÄH1299-tet on-PAD4ϸ°û´Óƽ°å ÉÏø½âÏÂÀ´£¬È»ºó·Ö±ðºÍչʾ¿¹PAD4µÄµ¥Á´¿¹Ìå»ò¿¹DIG±êÇ©µÄµ¥Á´¿¹Ìå²¢´øÓÐGFPmut2 Ó«¹âµÄϸ¾úÔ­ÉúÖÊÌå·õÓý¡£·õÓýÍêºó£¬È¥µôδ½áºÏµÄϸ¾úÔ­ÉúÖÊÌå¡£½«Ï¸°ûÖØÐüºóÔÚÁ÷ʽ ϸ°ûÒÇÉϼì²â¡£ÓÉÓÚϸ°ûºÍϸ¾úÔ­ÉúÖÊÌåÔÚ´óСÉÏÓÐÃ÷ÏÔ²î±ð£¬ÔÚÁ÷ʽϸ°ûÒÇÉÏ¿ÉÒÔͨ¹ý ǰÏòÉ¢Éä¹âFSCºÍ²âÏòÉ¢Éä¹âSSCÐźÅÃ÷ÏÔµÄÇø·Ö¿ª¡£H1299ϸ°ûÔÚÁ÷ʽϸ°ûÒÇÉϳÊÏÖ±È Ï¸¾úÔ­ÉúÖÊÌå¸ü´óµÄFSCºÍSSCÐźţ¬¿ÉÒÔ׼ȷµÄѡȡϸ°ûȺ£¬·ÖÎöϸ°ûÒòΪ½áºÏÁËÓÐÓ«¹â µÄϸ¾úÔ­ÉúÖÊÌå¶ø»ñµÃµÄGFPÓ«¹â¡£Ó«¹âµÄÇ¿Èõ¾ÍÄÜ·´Ó³³öϸ¾úÔ­ÉúÖÊÌå½áºÏµÄÇ¿Èõ¡£ÏÂÊöʵʩÀýÖÐËùʹÓõÄʵÑé·½·¨ÈçÎÞÌØÊâ˵Ã÷£¬¾ùΪ³£¹æ·½·¨¡£ÏÂÊöʵʩÀýÖÐËùÓõIJÄÁÏ¡¢ÊÔ¼ÁµÈ£¬ÈçÎÞÌØÊâ˵Ã÷£¬¾ù¿É´ÓÉÌҵ;¾¶µÃµ½¡£ÊµÊ©Àý1¡¢É¸Ñ¡¿¹ÌåµÄ·½·¨Ò»¡¢½«¿¹Ô­PAD4չʾÓÚÀëÌåµÄ¶¯Îïϸ°û±íÃæÈË·ÇСϸ°û·Î°©Ï¸°ûÖêH1299ϸ°û¹º×ÔÖйúҽѧ¿ÆÑ§ÔºÖ×Áöϸ°û¿â£¬²úƷĿ¼ºÅ Ϊ 0092¡£pUHDlO-3ÔØÌåÔÚÎÄÏ×(Gossen M, Bujard H :Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 1992,89(12) :5547_5551.)Öй«¿ª¹ý¡£(Domain 4 of the Anthrax Protective Antigen gene)°×É×IS Âë»ùÒòÐòÁÐÈçSEQ ID N0:5Ëùʾ¡£ÈËϸ°ûmRNA·­Òë³£ÓõÄÃÜÂë×ÓÓëϸ¾úÓÐËù²îÒ죬ÈËÔ´»¯ ¸ÃDNAµÄÄ¿µÄÊÇΪÁËÈËϸ°ûµÄ·­Òë»úÆ÷ÄܸßЧµØ·­Òë¸Ã»ùÒòת¼³öÀ´µÄmRNA¡£pDisplay(¹º×ÔInvitrogen)ÊDz¸È鶯Îïϸ°û±í´ïÔØÌ壬רÃÅÓÃÓÚ½«ÖØ×éµ°°×¶¨ λÓÚ²¸È鶯Îïϸ°ûĤ±íÃæ¡£Í¨¹ý½«¸ÐÐËȤµÄ»ùÒò¿Ë¡µ½ÔØÌå¿ò¼Ü(°üÀ¨N¶ËIg k·ÖÃÚÐÅ ºÅ£¬C ¶ËѪС°åÀ´Ô´µÄÉú³¤Òò×ÓÊÜÌå(PDGFR) (Gronwald RG, Grant FJ, Haldeman ¦¢¦¡, HartCE, Of Hara PJ, Hagen FS,Ross R,Bowen-Pope DF, Murray MJ :Cloning and expression of a cDNA coding for the human platelet-derived growth factor receptor :evidence for more than one receptor class. Proc Natl Acad Sci USA 1988,85(10) :3435_3439.) µÄ¿çĤ궨ÓòÖУ¬¶øÊ¹±í´ïµÄµ°°×Öʶ¨Ïò궨ÓÚϸ°û±íÃæ¡£PAD4ͨ¹ýC¶ËÓëѪС°åÀ´Ô´µÄ Éú³¤Òò×ÓÊÜÌå(PDGFR)µÄ¿çĤ궨ÓòÈÚºÏÔÚN¶Ë·ÖÃÚÐźŵÄÒýµ¼Ï´ӶøÄܹ»Õ¹Ê¾µ½H1299 ϸ°ûĤ±íÃæ¡£ÒÔ pDisplay Ϊģ°å£¬ÓÃÒýÎï¶Ô(ÉÏÓÎÒýÎï ACGCGAATTCGCCACCATGGAGACAGACACACTC CTGCT£¬ÏÂÓι­Ø­Îï AACTAGTCTAGACTAACGTGGCTTCTTCTGCCAAAGCAT)½øÐÐ PCR À©Ôö£¬À©Ôö²úÎïÖÐ °üÀ¨ÔØÌåÉϵÄIg kÁ´Ç°µ¼ÐòÁÐ(·ÖÃÚÐźÅ)¡¢HA±êÇ©¡¢¶à¿Ë¡λµãÇø¡¢c-myc±êÇ©¼°PDGFR ¿çÄ¤Çø¡£½«PCRÀ©Ôö²úÎï²åÈëpUHD10-3ÔØÌåÖÐËÄ»·Ëص÷¿ØµÄÆô¶¯×ÓÏÂÓεÄEcoR IºÍXba IÖ®¼ä£¬µÃµ½¹¹½¨ÕýÈ·µÄÖØ×éÖÊÁ££¬¼Ç×÷pUHD10-3-displayÔØÌå¡£¸ÃpUHDlO-3-displayÔØ ÌåÖÐͨ¹ýËÄ»·ËØÀ´µ÷½ÚÍâÔ´µ°°×(PAD4)ÔÚϸ°û±íÃæµÄ±í´ï¡£ÓÃoverlap PCRµÄ·½·¨ºÏ³ÉÈËÔ´»¯µÄPAD4 DNAÐòÁУ¬¾ßÌåÈçÏÂ×é×°PAD4µÄ¹­IÎïÐòÁÐ1 TCAGagatctCGGTTCCACTATGATCGGAACAACATCGCAGTCG 342 TGAGCTTCCTTCACGACGCTTTCGTCTGCGCCGACTGCGATGTTGTTCCG 503 GCGTCGTGAAGGAAGCTCACCGGGAAGTGATCAACAGCAGCACTGAAGGA 504 CGAATATCCTTATCGATGTTCAGGAGGAGTCCTTCAGTGCTGCTGTTGAT 505 CCTCCTGAACATCGATAAGGATATTCGGAAGATTCTGAGCGGCTACATCG 506 TTTGAGTCCCTCAGTATCTTCGATCTCCACGATGTAGCCGCTCAGAATCT 507 AGATCGAAGATACTGAGGGACTCAAAGAGGTCATCAACGATCGGTACGAT 508 CCTGTTGCAGGCTGCTGATATTGAGCATATCGTACCGATCGTTGATGACC 509 ATATCAGCAGCCTGCAACAGGACGGCAAAACTTTCATCGACTTCAAGAAA 5010 CAGAGGGAGCTTGTCGTTGTATTTCTTGAAGTCGATGAAAGTTTTGCC 4811 TACAACGACAAGCTCCCTCTGTACATTAGCAATCCCAACTACAAGGTGAA 5012 GTTCTCCTTTGTGACGGCATAGACGTTCACCTTGTAGTTGGGATTGCTAA 5013 TCTATGCCGTCACAAAGGAGAACACCATCATTAACCCAAGCGAGAACGGG 5014 GAGGATCCGTTTGATCCCATTTGTGGAAGTGTCCCCGTTCTCGCTTGGGT 5015 ACAAATGGGATCAAACGGATCCTCATCTTTTCCAAAAAGGGGTACGAGAT 5016 GTACgtcgacCCCAATCTCGTACCCCTTTTTGGAAAAGA 291.½«¸÷ÌõÒýÎïÖØÐüΪ100M¡£2.ÖÆ±¸10XµÄÒýÎï»ìºÏÎォÿÌõÒýÎï¸÷È¡11»ìºÏÔÚÒ»Æð£¬È»ºó¼ÓMilli-QË®ÖÁ ÖÕÌå»ý200 ¦Ì 1¡£3.ÖÆ±¸50 ¦Ì 1µÄPCR·´Ó¦Ìåϵa. 8 ¦Ì 1 10¦¶µÄÒýÎï»ìºÏÎï+5 ¦Ì 1 10¦¶ PCR»º³åÒºb. 1 ¦Ì 1 dNTP µ×Îï(2. 5mM each)c. 1 ¦Ì 1 pyrobest ¦£¡À|8| (Takara)d. 35 ¦Ì 1 Milli-Q Ë®4¡¤ PCR·´Ó¦Ìõ¼þ
a. 95 ¡ãC 2minb. 95¡ãC 20secc. 52 ¡ãC Imind. 72 ¡ãC 2mine.ÖØ¸´²½Öèb_d29´Îf. 72 ¡ãC IOmin5.È¡1 ¦Ì 1 PCR²úÎï(²»ÐèÒª´¿»¯)×÷Ϊģ°åÓÃÓÚµÚ¶þ´ÎPCRa. 1 ¦Ì 1 of PCR ²úÎïb. 5 ¦Ì 1 IOX PCR »º³åÒºc. 1 ¦Ì 1 dNTP µ×Îï(2. 5mM each)d. 0¡¤ 5¦Ì 1 1 ºÅÒýÎï(¦©¦¯¦¯¦Ì¦¬)e. 0. 5¦Ì 1 16 ºÅÒýÎï(¦©¦¯¦¯¦Ì¦¬)f. 1 ¦Ì 1 pyrobest À©Ôöø(Takara)g. 41 ¦Ì 1 Milli-Q Ë®h.ÖØ¸´²½Öè6µÄPCR·´Ó¦ÓÃBgl II-Sal IøÇн«À©Ôö²úÎï²¢Ñǿˡµ½pUHDlO-3-displayÔØÌåÖУ¬ÖØ×éÖÊ Á£½øÐвâÐòÑéÖ¤£¬½á¹ûÔÚpUHDlO-3-displayµÄBgl IIºÍSal IøÇÐλµã¼ä²åÈëÁË SEQ ID NO 5ËùʾDNA£¬±íÃ÷¹¹½¨µÄÖØ×éÖÊÁ£ÕýÈ·£¬¼Ç×÷pUHD10-3-display-PAD4¡£ÍêÈ«ÅàÑø»ùº¬10%СţѪÇå(Hyclone)ºÍ100U/mlË«¿¹(ÇàÁ´Ã¹ËØ£¬Sigma)µÄ DMEMÅàÑø»ù(Invitrogen)£¬ÓÃÓÚÅàÑøHI2"ϸ°û¡£ÔÚתȾ24Сʱǰ½ÓÖÖH1299ϸ°ûʹÆäÔÚתȾʱ´ïµ½60% _80%Âú¶È£¬È¥³ýÍêÈ«Åà Ñø»ù£¬ÓÃLipofectamine 2000 (Invitrogen)½«pTet-on (±àÂërtTAת¼Òò×Ó£¬¿ÉÓÚËÄ»·ËØ ÏìÓ¦Æô¶¯×ÓÅä¶Ô¶Ô»ùÒò½øÐÐTet onµ÷¿Ø)(Clontech)ºÍÄ¿µÄÖÊÁ£pUHD10-3-display-PAD4 ÔÚÎÞѪÇåÅàÑø»ùÖлìºÏ²¢¼ÓÈëϸ°ûÅàÑøÅÌÖУ¬·õÓý4-6Сʱºó£¬»»³ÉÍêÈ«ÅàÑø»ù¼ÌÐø ÅàÑø£¬×ªÈ¾24Сʱºó£¬½«Ï¸°û°´1 5µÄ±ÈÀý½ÓÖÖÓÚеÄÅàÑøÃóÖУ¬²¢¼ÓÈë450yg/ml G418 (Amersco)ɸѡ¿¹ÐÔϸ°û¡£É¸Ñ¡Á½Öܺ󣬽«G418¿¹ÐÔϸ°û°´5 X IO5ϸ°û/IOcmƽÃóµÄ ÃܶȽÓÖÖ£¬²¢¼ÓÈë2¦Ì g/ml d0XyCyCline(D0X£¬Ò»ÖÖËÄ»·ËصÄÑÜÉúÎ¾ßÓиüÇ¿µÄÓÕµ¼Ð§¹û ºÍÎȶ¨ÐÔ)(Sigma)ÓÕµ¼PAD4±í´ï¡£ÓÕµ¼48Сʱºó£¬ÊÕ¼¯Ï¸°û¡£Ï¸°û¼ø¶¨ÓÃ1 400Ï¡Ê͵Ŀ¹c-myc±êÇ©µÄµ¥¿¹(9E10£¬Calbiochem)4¶È±ê ¼Çϸ°û±íÃæµÄPAD4-c-mycµ°°×¡£·õÓý30minºó£¬ÔÙÓÃ1 300Ï¡Ê͵ÄÍÿ¹ÊóµÄFITC±ê ¼ÇµÄ¶þ¿¹(Jackson ImmunoResearch) 4¶È·õÓý30min¡£±»±ê¼ÇµÄϸ°ûÖØÐüÓÚDMEMÅàÑø»ù (Invitrogen,CA)ÖС£ÑùÆ·ÔÚBD FACS Aria II (Becton Dickinson)ÉϽøÐÐÎÞ¾ú·ÖÑ¡£¬½«Ô¼ 5%¾ßÓÐ×îÇ¿FITCÓ«¹âµÄϸ°û·ÖÑ¡³öÀ´¡£¾­¹ýÈýÂÖ·ÖÑ¡£¬»ñµÃÁË 63%µÄϸ°û±íÃæÕ¹Ê¾PAD4 µÄϸ°û£¬¼Ç×÷H1299-tet on PAD4ϸ°û¡£DoxÓÕµ¼Ç°ºóµÄH1299_tet on-PAD4ϸ°ûÈçͼ1Ëùʾ¡£Í¼1ÖУ¬(A)Ó«¹âÏÔ΢¾µ¹Û ²ìPAD4ÔÚH1299ϸ°û±íÃæµÄ±í´ï¡£¿¹c_myc±êÇ©¿¹Ìå±ê¼ÇH1299_tet on_PAD4ϸ°ûÔÚÓÐ ÎÞDoxʱ±íÃæPAD4µÄ±í´ïˮƽ¡£(B)Á÷ʽϸ°ûÒǼì²âH1299-tet on_PAD4ϸ°ûÔÚÓÐÎÞDox ʱ±íÃæPAD4µÄ±í´ïˮƽ¡£±íÃ÷£¬ÔÚϸ°ûά³ÖµÄ¹ý³ÌÖУ¬ÓÉÓÚûÓÐDox£¬Ï¸°û²»»á±í´ïPAD4¿¹ Ô­£¬ÓÐÀûÓÚϸ°ûµÄÀ©Ôö¡£Ö»Óе±ÔÚÅàÑø»ùÖмÓÈëDoxʱ£¬H1299ϸ°û²ÅÄÜÔÚ¶Ìʱ¼äÄÚÔÚϸ°û±íÃæ±í´ïPAD4¿¹Ô­¡£¶þ¡¢½«´ýɸѡ¿¹ÌåչʾÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæÏ¸¾ú±í´ïÔØÌå pBAD30-KmR-GFPmut2¡¢pAK200-26_10 (anti-Digoxigenin scFv) ºÌ¿Ú pAK200-M18 ÔÚÎÄÏ×(Jung ST, Jeong KJ, Iverson BL, Georgiou G=Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens. Biotechnol Bioeng 2007,98(1) 39-47.)Öй«¿ª¹ý¡£pAK200-M18Öк¬ÓÐPAD4µÄ¿¹Ìå(¼´M18)µÄ±àÂë»ùÒò£¬¸Ã»ùÒòÐòÁÐÈçSEQ ID NO 1Ëùʾ¡£M18¿¹ÌåµÄ°±»ùËáÐòÁÐÈçSEQ ID N0:2Ëùʾ¡£pAK200-26-10Öк¬ÓÐÒõÐÔ¶ÔÕÕ¿¹Ìå26_10 (¿¹µØ¸ßÐÁ±êÇ©(DIG)µÄ¿¹Ìå)µÄ±àÂë »ùÒò£¬¸Ã»ùÒòÐòÁÐÈçSEQ ID N0:3Ëùʾ¡£¶ÔÕÕ¿¹Ìå26-10µÄ°±»ùËáÐòÁÐÈçSEQ ID NO :4Ëù
7J\ ¦ÏpBAD30-KmRÔØÌåÊÇÒ»¸öaraBADÆô¶¯×ÓÑϸñµ÷¿Øµ°°×±í´ïµÄÔØÌå¡£Ïòϸ¾úÖе¼ÈëpBAD30-KmR-GFPmut2µÄÄ¿µÄÊÇʹϸ¾úÔ­ÉúÖÊÌå·¢Ó«¹â£¬±ãÓÚɸѡ¡£pAK200ÔØÌåÊÇÒ»ÖÖÊɾúÌåչʾµÄÔØÌ壬Ëü½«ÍâÔ´µ°°×µÄC¶ËÓëM13ÊɾúÌåµÄgp3 µ°°×ÐγÉÈںϵ°°×£¬Í¨¹ýgp3궨ÔÚϸ¾úÄÚĤÍâ²à´Ó¶ø½«ÍâÔ´µ°°×չʾÔÚϸ¾úÖÜÖʿռä¡£ ½«Ï¸¾úÍâ±ÚÈ¥³ýºó½«Äܽ«Ä¿µÄµ°°×չʾÔÚϸ¾ú±íÃæ¡£E. coli Jude-I ÔÚÎÄÏ×(F£¬[TnlO (Tetr) proAB+lacIq ¦¤ (lacZ)M15]mcrA ¦¤ (mrr-hsdRMS-mcrBC) ¦µ80(11¦Â¦Ï¦¦¦¤¦¬15 ¦¤ lacX74 deoR recAl araD139A (ara leu) 7697 galU galK rpsL endAl nupG)(Jung ST,Jeong KJ,Iverson BL,Georgiou G :Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens. Biotechnol Bioeng 2007,98(1) 39-47.)Öй«¿ª¹ý¡£E coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°ûµÄÖÆ±¸A.ÌôÈ¡µ¥¿Ë¡½ÓÖÖÓÚ5ml SOBÅàÑø»ùÖÐ37¶È£¬250rpmÅàÑø16Сʱ£»B.½«5ml¹ýÒ¹ÅàÑøÒº½ÓÖÖÓÚ500ml SOBÅàÑø»ùÖУ¬37¶È£¬250rpmÅàÑøÖÁ0D600µ½ 1. O £»C.½«ÅàÑøÒºÖÃÓÚ±ùÉÏ30·ÖÖÓ£¬È»ºó4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓÊÕ¼¯Ï¸¾ú£»D.ÆúÉÏÇ壬ÓÃ500ml±ùÉÏÔ¤ÀäµÄÎÞ¾ú³¬´¿Ë®ÖØÐü¾úÌåE. 4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓ£¬ÆúÉÏÇ壬ÓÃ250ml±ùÉÏÔ¤ÀäµÄÎÞ¾ú³¬´¿Ë®ÖØÐü¾úÌåF. 4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓ£¬ÆúÉÏÇ壬ÓÃ50ml±ùÉÏÔ¤ÀäµÄÎÞ¾ú³¬´¿Ë®ÖØÐü¾úÌåG. 4£¬500g 4¶ÈÀëÐÄ15·ÖÖÓ£¬ÆúÉÏÇ壬ÓÃ1. 5ml±ùÉÏÔ¤ÀäµÄ10% (¦Í/¦Í)¸ÊÓ͵ÄÎÞ¾ú ³¬´¿Ë®ÈÜÒºÖØÐü¾úÌ壬50 ¦Ì 1/¹Ü·Ö×°¸ÐÊÜ̬ϸ°û£¬ÂíÉÏÖÃÓÚ-70¶È³¬µÍαùÏä±£´æ¡£µçת»¯E coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°ûA.½«0. IcmµÄµç»÷±­ÖÃÓÚ±ùÉÏÔ¤À䣬ͬʱ´Ó_70¶È³¬µÍαùÏäÈ¡³öÒ»¹ÜE coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬ÖÃÓÚ±ùÉÏÈÚ»¯¡£B.½«ÖÊÁ£ÈÜÒº(1-2 ¦Ì 1)¼ÓÈëÒÑÈÜ»¯µÄE coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°ûÖУ¬Ñ¸ËÙ ²¢Îºͻì„ò¡£C.ÂíÉϽ«¸ÐÊÜ̬-ÖÊÁ£»ìºÏÎï×ªÒÆµ½0. IcmµÄµç»÷±­ÖУ¬½«µç»÷±­ÖÃÓÚGene
12Pulser II (Bio-Rad)µç´©¿×ÒÇÉÏ£¬ÒÔ1. 8kv£¬25 ¦Ì F£¬200 ¦¸µÄµç»÷Ìõ¼þ½øÐеç»÷¡£µç»÷³£ Êý¿É¿ØÖƵ½4-5ºÁÃë¡£D.ѸËÙ¼ÓÈëIml SOCÅàÑø»ù(³£ÎÂ)ÖØÐüµç»÷ºóµÄϸ¾ú£¬²¢×ªÒƵ½Ò»¸ö15mlÀëÐÄ ¹ÜÖУ¬ÖÃÓÚ37¶ÈÒ¡´²£¬220rpmÅàÑø1¸öСʱ¡£E.½«¸´ËÕºóµÄ¾úÒºÒÔ300 ¦Ì l/10cmƽÃóÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØºÍ¿¨ÄÇÃ¹ËØµÄLB¹ÌÌå Ñ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£°´ÕÕÈçÉÏ·½·¨½«pBAD30-KmR-GFPmut2ºÍpAK200-26-10¹²Í¬×ªÈëE.coli Jude-I£¬ µÃµ½º¬ÓÐ pBAD30-KmR-GFPmut2 ºÍ pAK200-26_10 µÄ E. coli Jude-I¡£°´ÕÕÈçÉÏ·½·¨½«pBAD30-KmR-GFPmut2ºÍpAK200-M18¹²Í¬×ªÈëE.coli Jude-I£¬µÃ µ½º¬ÓÐ pBAD30-KmR-GFPmut2 ºÍ pAK200_M18 µÄ E. coli Jude-I¡£½«º¬ÓÐpBAD30-KmR-GFPmut2 ºÍ pAK200-26_10 µÄ E.coli Jude-I »òº¬ÓÐ pBAD30-KmR-GFPmut2 ºÍ pAK200_M18 µÄ E. coli Jude-I ÔÚÌí¼ÓÁË 20mg/ml ÆÏÌÑÌÇ£¬40 ¦Ì g/ mlÂÈÃ¹ËØ(Sigma)ºÍ50 ¦Ì g/ml¿¨ÄÇÃ¹ËØ(Sigma)µÄTB (Terrific Broth)ÅàÑø»ùÖÐÅàÑø 37¶È¹ýÒ¹¡£½«¹ýÒ¹ÅàÑøÒº°´1 100µÄ±ÈÀý½ÓÖÖµ½ÐÂÏʵÄTBÅàÑø»ùÖÐ(²»º¬ÆÏÌÑÌÇ)£¬37 ¶ÈÅàÑøÖÁ OD6tltl µÈÓÚ 0. 5¡£È»ºó¼ÓÈë ImM IPTG(Sigma)ºÍ 2mg/ml L-arabinose (Sigma)ÖÁÓÚ 16¶ÈÓÕµ¼¿¹ÌåºÍÂÌɫӫ¹âµ°°×µÄ±í´ï¡£ÖƱ¸Ï¸¾úÔ­ÉúÖÊÌåÓÕµ¼18Сʱºó£¬ÀëÐÄÊÕ¼¯¾úÌå(¾úÌåŨ¶ÈΪIml¾úÌåµÄ OD6tltl ֵΪ 4. 5)£¬Óà Iml IOmM Tris-HCl(pH 8. 0)Ï´Á½´Î£¬ÔÙÖØÐüÓÚ Iml STE ÈÜÒºÖÐ(0. 5M Sucrose, IOmM Tris-HCl, IOmM EDTA£¬pH 8¡¤ 0)£¬ÖÃÓÚ 37 ¶È·õÓý 30min¡£12£¬000g ÀëÐÄÊÕ¼¯Ï¸ ¾ú£¬È»ºóÓÃÈÜÒº A (0. 5M Sucrose, 20mM MgCl2, IOmM M0PS£¬pH 6.8)Ï´Ò»´Î£¬ÔÙÖØÐüÓÚ Iml º¬ ÓÐlmg/mlÈܾúøµÄÈÜÒºAÖУ¬37¶È·õÓý15min¡£×îºó12£¬OOOgÀëÐÄÊÕ¼¯Ï¸¾úÔ­ÉúÖÊÌ壬²¢ ÖØÐüÓÚº¬ÓÐBSAºÍÍÑÖ¬ÄÌ·Û¡¢pH6. 5µÄoptimal-MEMÅàÑø»ùÖУ¬ÖÁϸ¾úÔ­ÉúÖÊÌåµÄ Ũ¶ÈΪImlÐüÒºµÄ0D_ֵΪ10£¬»ñµÃϸ¾úÔ­ÉúÖÊÌåÐüÒº¡£Èý¡¢¿¹Ìåɸѡ·½·¨µÄÃþË÷Doxycycline ¹º×Ô Sigma£¬²úƷĿ¼ºÅΪ D9891¡£optimal-MEM ÅàÑø»ù¹º×Ô Invitrogen£¬²úƷĿ¼ºÅΪ31985¡£(Ò» )Ñé֤ƽ°åÌÔÑ¡·¨(panning)ÄÜ·ñÓÃÓÚ¿¹ÌåɸѡʵÑé×é·½·¨(A)½«H1299-tet on_PAD4ϸ°û°´5X IO5ϸ°û/IOcmƽÃó½ÓÖÖ£¬²¢¼Ó Èë2¦Ì¦Â/¦Ð¦É1 doxycyclineÓÕµ¼PAD4±í´ï¡£ÓÕµ¼60Сʱºó£¬Æ½ÃóÓÃPBSÏ´Ò»±é£¬È»ºó¼ÓÈ뺬 ÓÐBSAºÍÍÑÖ¬ÄÌ·ÛµÄoptimal-MEM pH6. 5ÅàÑø»ù³£Î·â±Õ20min¡£½«IOmlϸ¾úÔ­ ÉúÖÊÌåÐüÒº(10mlϸ¾úÔ­ÉúÖÊÌåÐüÒºµÄOD6tltlֵΪ80)¼ÓÈ뵽ÿ¸öƽÃóÖУ¬·ÅÖÃÓÚ37¶È¡¢pH Öµ6. 5¡¢Ë®Æ½Ò¡´²ÖÐÒÔ50ת/·ÖÖÓ·õÓý1Сʱ¡£·õÓý½áÊø£¬ÓÃPBSÏ´Èý´Î£¬È¥³ýδ½áºÏµÄϸ ¾úÔ­ÉúÖÊÌ塣ʵÑéÖе¥¶À¼ÓչʾM18µÄϸ¾úÔ­ÉúÖÊÌå»òչʾ26-10µÄϸ¾úÔ­ÉúÖÊÌå¡£ÓÉÓÚϸ¾úÔ­ÉúÖÊÌå´øÓÐGFPÓ«¹â£¬Ö±½ÓÔÚÓ«¹âÏÔ΢¾µÏ¹۲ìϸ¾úÔ­ÉúÖÊÌåÓëϸ°û µÄ½áºÏ¡£½á¹ûÈçͼ2Ëùʾ¡£Í¼2AΪչʾM18µÄϸ¾úÔ­ÉúÖÊÌåÓëH1299-tet on-PAD4·õÓý£» ͼ2BΪչʾ26-10ϸ¾úÔ­ÉúÖÊÌåÓëH1299-tet on_PAD4·õÓý£»Í¼2CΪչʾM18ϸ¾úÔ­Éú ÖÊÌåÓëH1299ϸ°û·õÓý£»Í¼2DΪչʾ26-10ϸ¾úÔ­ÉúÖÊÌåÓëH1299ϸ°û·õÓý¡£Í¼2AÏÔʾ ÎªÌØÒì½áºÏʵÑ飬¶øÍ¼2B¡¢CºÍDΪ¶ÔÕÕʵÑ顣ʵÑéÉè3´ÎÖØ¸´£¬½á¹ûÒ»Ö¡£½á¹û±íÃ÷£¬Ö»ÓРչʾÁË¿¹PAD4µÄµ¥Á´¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌåÄܽáºÏµ½H1299-tet on_PAD4ϸ°ûµÄ±íÃæ£¬¶øÕ¹Ê¾¿¹DIG±êÇ©µÄϸ¾úÔ­ÉúÖÊÌå²»ÄÜÓëH1299-tet0n-PAD4ϸ°û½áºÏ¡£Á½ÖÖϸ¾úÔ­ÉúÖÊÌåϸ °û¾ù²»ÄÜºÍÆÕͨµÄH1299ϸ°û½áºÏ¡£Ö¤ÊµM18-ϸ¾úÔ­ÉúÖÊÌåÄܽáºÏµ½Ìù±ÚµÄH1299-PAD4 ϸ°û±íÃæ¡£ÇÒ¶ÔÕÕ¿¹ÌåµÄ·ÇÌØÒì½áºÏˮƽ·Ç³£µÍ¡£Ö¤Ã÷ƽ°åÌÔÑ¡·¨¿ÉÒÔÓÃÓÚɸѡ¿¹Ìå¡£(¶þ)ÑéÖ¤Á÷ʽ·ÖÑ¡ÄÜ·ñÓÃÓÚ¿¹ÌåɸѡÊÕ¼¯ÓÕµ¼¹ýµÄH1299-tet on_PAD4ϸ°û£¬ÖØÐüÓÚº¬ÓÐIOmM EDTAºÍ1 % BSA optimal-MEM pH6. 5 ÅàÑø»ùÖС£½« IO6 H1299_tet on_PAD4 ϸ°ûÓë Iml 0D_ ֵΪ 2 µÄչʾ M18µÄϸ¾úÔ­ÉúÖÊÌå»òչʾ26-10µÄϸ¾úÔ­ÉúÖÊÌåÐüÒº(ImlÐüÒºµÄOD6tltlֵΪ2)»ìºÏ£¬Öà ÓÚ¾²Òô»ìºÍÆ÷ÉÏÓÚ37¶È¡¢pH6. 5µÄÌõ¼þÏ·õÓý1Сʱ¡£·õÓýÍêºó£¬300gÀëÐÄ2·ÖÖÓÒÔ³ýÈ¥ δ½áºÏµÄϸ¾úÔ­ÉúÖÊÌå¡£ÑùÆ·ÖØÐüÓÚDMEMÅàÑø»ùÖУ¬ÓÃÁ÷ʽϸ°ûÒÇBD FACS Calibur flow cytometer (Becton Dickinson)½øÐзÖÎö¡£Í¼3AΪϸ¾úÔ­ÉúÖÊÌåºÍH1299ϸ°ûͨ¹ý¿¹ÌåM18 ºÍ¿¹Ô­PAD4½áºÏÔÚÒ»ÆðµÄʾÒâͼ¡£H1299-tet on-PAD4ϸ°ûÃ÷ÏÔ±Èϸ¾úÔ­ÉúÖÊÌå´ó£¬ÔÚÁ÷ ʽϸ°ûÒÇÉϱíÏÖ³ö¸üÇ¿µÄǰÏòÉ¢Éä¹âºÍ²àÏòÉ¢Éä¹âÐźţ¬Í¨¹ýÉ¢Éä¹âÐźſÉÒÔ½«Ï¸°ûºÍ²Ð ÁôµÄϸ¾úÔ­ÉúÖÊÌåÇø·Ö¿ªÀ´(ͼ3B)¡£Í¼3BÖÐRlÇøÓòΪH1299-tet on_PAD4ϸ°û¼°Ä¿µÄ¸´ ºÏÎï¡£½«¸ÃRlÇøÓòÄÚµÄϸ°ûºÍϸ°û_ϸ¾úÔ­ÉúÖÊÌå¿ÉÒÔͼʾΪͼ3C¡£H1299-tet on-PAD4 ϸ°û½áºÏչʾM18ϸ¾úÔ­ÉúÖÊÌ壬¶ø²»½áºÏÓÃÓÚÒõÐÔ¶ÔÕÕµÄչʾ26-10ϸ¾úÔ­ÉúÖÊÌå¡£Á½ ÖÖϸ¾úÔ­ÉúÖÊÌå¾ù±í´ïÂÌɫӫ¹âµ°°×GFPmut2£¬Òò´Ë±»488nm¼¤¹â¼¤·¢ºó·¢ÂÌɫӫ¹â¡£ÓÉ Í¼3C¿É¼û£¬ÒòչʾM18ϸ¾úÔ­ÉúÖÊÌåÄÜÌØÒì½áºÏH1299-tet on-PAD4ϸ°û¿É¼ì²âµ½Ã÷ÏÔ µÄ530/30nm²¨³¤µÄÓ«¹âÐźţ»¶øÕ¹Ê¾26-10ϸ¾úÔ­ÉúÖÊÌ弸ºõ²»½áºÏH1299_tet on-PAD4 ϸ°û£¬Ö»Äܼì²âµ½·Ç³£µÍˮƽµÄ±³¾°Ó«¹â¡£ÑùÆ·¿ÉÓÃÁ÷ʽ·ÖÑ¡ÒÇFACSAria II (Becton Dickinson£¬Ò²¿ÉÓñðµÄÁ÷ʽ·ÖÑ¡ÒÇ)¸ù¾ÝÓ«¹âÐźŷÖÑ¡H1299_tet on-PAD4ϸ°ûÓëÕ¹ ʾM18¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌåµÄ¸´ºÏÎͼ3CÖÐSÇøÓòΪ·ÖÑ¡Çø¡£½á¹ûɸѡµ½H1299-tet on-PAD4ϸ°ûÓëչʾM18¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌåµÄ¸´ºÏÎ±íÃ÷Á÷ʽ·ÖÑ¡·¨Ò²¿ÉÓÃÓÚ¿¹Ìåɸ Ñ¡¡£(Èý)·õÓýÌõ¼þµÄÓÅ»¯½«ÓÕµ¼¹ýµÄH1299-tet on_PAD4ϸ°ûÊÕ¼¯²¢ÖØÐüÓÚº¬ÓÐIOmM EDTAºÍ1 % BSA¡¢pH ²»Í¬µÄoptimal-MEMÅàÑø»ùÖС£½«IO6ϸ°ûÓëImlչʾM18ϸ¾úÔ­ÉúÖÊÌåÐüÒº(ImlÐüÒºµÄ 0D_ֵΪ2)»ìºÏ£¬ÖÃÓÚ¾²Òô»ìºÍÆ÷ÉÏÓÚ37¶È¡¢pH²»Í¬µÄÌõ¼þÏ·õÓý1Сʱ¡£pHÖµ·Ö±ðΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0£¬7. 3 »ò 7. 5¡£·õÓýÍê³ÉµÄÑùÆ·ÔÚÁ÷ʽ·ÖÑ¡ÒÇFACSAria II (Becton Dickinson)Éϼì²âϸ¾úÔ­Éú
ÖÊÌå½áºÏÐźÅ¡£Í¬Ê±ÒÔչʾ26-10¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌå×÷Ϊ¶ÔÕÕ¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûȡƽ¾ùÊý¡£Í¼4Ϊչʾ¿¹PAD4¿¹ÌåM18ϸ¾úÔ­ÉúÖÊÌå»òÒõ ÐÔ¶ÔÕÕչʾ26-10¿¹Ìåϸ¾úÔ­ÉúÖÊÌåÔÚ²»Í¬µÄpHÖµÌõ¼þÏÂÓëÐü¸¡µÄH1299-tet on-PAD4 ϸ°û½áºÏÊýÄ¿¡£ÔÚpHΪ5. 5µ½7. 0Ö®¼ä£¬Õ¹Ê¾M18µÄϸ¾úÔ­ÉúÖÊÌåÓëH1299_tet on_PAD4 ϸ°ûµÄ½áºÏÊý(ÔÚÁ÷ʽÖÐÒÔGFPÓ«¹âÇ¿¶È±íʾ)Ã÷ÏÔ¸ßÓÚ´ËpHÖµ·¶Î§Ö®ÍâչʾM18µÄϸ ¾úÔ­ÉúÖÊÌåÓëH1299-tet on-PAD4ϸ°ûµÄ½áºÏÊý¡£¶øÔÚpHΪ5. 5µ½7. 0Ö®¼äºÍÖ®Í⣬չʾ ÒõÐÔ¶ÔÕÕ¿¹Ìå26-10µÄϸ¾úÔ­ÉúÖÊÌåÓëH1299-tet on-PAD4ϸ°ûµÄ½áºÏÊý¶¼´¦ÓÚµÍˮƽ״ ̬¡£ÀýÈçÕ¹Ê¾ÌØÒ쿹ÌåM18µÄϸ¾úÔ­ÉúÖÊÌåÓëH1299-tet on_PAD4ϸ°û·õÓýºó£¬µ±pHֵΪ 5. 0ʱ£¬½áºÏÐźÅ(Ó«¹âÇ¿¶È)Ϊ662 £»µ±pHֵΪ5. 5ʱ£¬½áºÏÐźÅΪ1136 £»µ±pHֵΪ6. 0ʱ£¬½áºÏÐźÅΪ2857 £»µ±pHֵΪ6. 5ʱ£¬½áºÏÐźÅΪ2711 £»µ±pHֵΪ7. 0ʱ£¬½áºÏÐźÅΪ 839 £»µ±pHֵΪ7. 5ʱ£¬½áºÏÐźÅΪ439¡£ÒÔÉÏʵÑé˵Ã÷pHÔÚ5. 5µ½7. 0Ö®¼äÓÐÀûÓÚ¶ÔÕ¹ Ê¾ÌØÒ쿹ÌåM18µÄϸ¾úÔ­ÉúÖÊÌåµÄ¸»¼¯¡£µ±pHÖµ´¦ÓÚÉúÀíÌõ¼þpH7. 5ʱ£¬ÌØÒì½áºÏÐźŷdz£µÍ¡£¶øpHÖµ½µµ½ÈõËáÐÔʱ£¬½á ºÏÐźÅÓÐÃ÷ÏÔÌá¸ß¡£ÕâºÜ¿ÉÄÜÊÇÒòΪÔÚÉúÀíÌõ¼þϲ¸È鶯Îïϸ°ûºÍϸ¾ú±íÃæ¶¼´øÓиºµç ºÉ£¬½µµÍPH¿ÉÒÔÖкͲ¿·Ö¸ºµçºÉ£¬½µµÍÁ½ÕßÖ®¼äµÄ¾²µçÅų⣬´Ó¶øÓÐÀûÓÚ¿¹Ô­-¿¹ÌåµÄ½á ºÏ¡£µ«PHÖµ¹ýµÍ£¬½áºÏÐźÅÒ²»á¿ªÊ¼Ï½µ¡£Õâ¿ÉÄÜÊÇÓÉÓÚPAD4µ°°×½âÕÛµþÔì³É¿¹Ô­±íλ ±ä»¯µÄÔ­Òò¡£×ۺϿ¼ÂǽáºÏÐźż°µ°°×½á¹¹Îȶ¨ÐÔµÄË«ÖØÒòËØ£¬Ñ¡¶¨ÔÚPH6. 5×÷Ϊ×îÓÅÌõ ¼þ¡£ËÄ¡¢¿¹Ìåɸѡ( Ò» )ƽ°åÌÔÑ¡·¨(panning)½«Õ¹Ê¾26-10¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌåµÄÐü¸¡ÒºÓëչʾM18µÄϸ¾úÔ­ÉúÖÊÌåµÄÐü¸¡Òº »ìºÏ£¬µÃµ½»ìºÏÐü¸¡Òº£¬Ê¹»ìºÏÐü¸¡ÒºÖÐչʾM18µÄϸ¾úÔ­ÉúÖÊÌåÓëչʾ26-10¿¹ÌåµÄϸ¾ú Ô­ÉúÖÊÌåµÄÊýÄ¿±ÈΪ1 1000»ò5 100£¬È»ºó½«»ìºÏÐü¸¡Òº·Ö±ðÓÃÆ½°åÌÔÑ¡·¨½øÐÐɸѡ ¿¹Ìå¡£½«H1299_tet on_PAD4ϸ°û°´5 X IO5ϸ°û/IOcmƽÃó½ÓÖÖ£¬ÔÚÍêÈ«ÅàÑø»ùÖмÓÈë 2 ¦Ì g/ml doxycycline£¬ÓÕµ¼PAD4±í´ï¡£ÓÕµ¼60Сʱºó£¬Æ½ÃóÓÃPBSÏ´Ò»±é£¬È»ºó¼ÓÈ뺬ÓÐ 1% BSAºÍÍÑÖ¬ÄÌ·ÛµÄoptimal-MEM pH6. 5ÅàÑø»ù³£Î·â±Õ20min¡£½«IOml»ìºÏÐü¸¡ Òº(IOml»ìºÏÐü¸¡ÒºµÄOD6tltlֵΪ80)¼ÓÈ뵽ÿ¸öƽÃóÖУ¬·ÅÖÃÓÚ37¶È¡¢pHÖµ6. 5¡¢Ë®Æ½Ò¡ ´²ÖÐÒÔ50ת/·ÖÖÓ·õÓý1Сʱ¡£·õÓý½áÊø£¬ÓÃPBSÏ´Èý´Î£¬È¥³ýδ½áºÏµÄϸ¾úÔ­ÉúÖÊÌ壬±£ ÁôÊ£Óà²úÎï¡£»ñµÃ¿¹ÌåÐòÁн«Ê£Óà²úÎïÓÃÒÈøø½â£¬´ÓÖлØÊÕ±í´ï¿¹ÌåµÄÖÊÁ££¬½«»ØÊյıí´ï ¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄ LB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£´ÓÑôÐÔת»¯×ÓÖÐÌáÈ¡ÖÊÁ££¬½øÐвâÐò£¬µÃµ½Ä¿µÄ¿¹ÌåµÄ±à Âë»ùÒòÐòÁУ¬ÐòÁÐÈçSEQ ID NO :1Ëùʾ£¬»ùÒòÐòÁÐÕýÈ·£¬ËµÃ÷±¾·¢Ã÷·½·¨Äܹ»É¸Ñ¡µÃµ½ÕýÈ· µÄ¿¹Ìå¡£ÔÙͨ¹ý»ùÒò¹¤³Ì±í´ïºÍ´¿»¯µÃµ½Ä¿µÄ¿¹Ì塣ͳ¼Æ¸»¼¯Ð§Âʽ«Ê£Óà²úÎïÓÃÒÈøø½â£¬´ÓÖлØÊÕ±í´ï¿¹ÌåµÄÖÊÁ££¬½«»ØÊյıí´ï ¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄ LB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Ëæ»úÌôÈ¡48¸öת»¯×Ó£¬²ÉÓþúÂäPCR¼ø¶¨¸»¼¯ºóµÄM18 ´¿¶È£¬ÔÙͳ¼Æ¸»¼¯Ð§ÂÊ¡£¸»¼¯Ð§ÂʵļÆË㹫ʽ¸»¼¯ºóµÄM18´¿¶È/¸»¼¯Ç°µÄM18´¿¶È¡£¼ø¶¨ÒýÎïÐòÁÐ(M18ÌØÒìÒýÎï)ÈçÏÂ5¡¯ -ATATGCTAGCGATATTCAGATGACACAGACT-3¡¯ £»5 ¡¯ -GCGTTTGCCATCTTTTCATAATCAAAATCACC-3¡¯¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûȡƽ¾ùÊý¡£½á¹ûÈçͼ5Ëùʾ¡£µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔ­ÉúÖÊÌåµÄ´¿¶ÈΪ 0. 1 %ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ6. 4%£¬ÌÔÑ¡±íÏÖ³öºÃµÄ¸»¼¯Ð§ÂÊ£¬Îª64±¶¡£µ±ÓÃÓÚʵÑéµÄ»ì ºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔ­ÉúÖÊÌåµÄ´¿¶ÈΪ5%ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ25%£¬ÌÔÑ¡µÄ¸»¼¯ ЧÂÊΪ5±¶¡£µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£
µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£(¶þ)Á÷ʽ·ÖÑ¡·¨½«Õ¹Ê¾26-10¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌåµÄÐü¸¡ÒºÓëչʾM18µÄϸ¾úÔ­ÉúÖÊÌåµÄÐü¸¡Òº »ìºÏ£¬µÃµ½»ìºÏÐü¸¡Òº£¬Ê¹»ìºÏÐü¸¡ÒºÖÐչʾM18µÄϸ¾úÔ­ÉúÖÊÌåÓëչʾ26-10¿¹ÌåµÄϸ¾ú Ô­ÉúÖÊÌåµÄÊýÄ¿±ÈΪ1 1000»ò5 100£¬È»ºó½«»ìºÏÐü¸¡Òº·Ö±ðÓÃÁ÷ʽ·ÖÑ¡·¨½øÐÐɸѡ ¿¹Ìå¡£½«H1299-tet on_PAD4ϸ°û°´5 X IO5ϸ°û/IOcmƽÃó½ÓÖÖ£¬ÔÚÍêÈ«ÅàÑø»ùÖмÓÈë 2 ¦Ì g/ml doxycycline£¬ÓÕµ¼PAD4±í´ï¡£ÓÕµ¼60Сʱºó£¬Æ½ÃóÓÃPBSÏ´Ò»±é£¬Ã¸½âÊÕ¼¯ÓÕµ¼ ¹ýµÄ H1299-tet on_PAD4 ϸ°û£¬²¢ÖØÐüÓÚº¬ÓÐ IOmM EDTA ºÍ 1 % BSA¡¢pH6. 5 µÄ optimal-MEM ÅàÑø»ùÖС£½«IO6CellsÓëIml»ìºÏÐü¸¡Òº(Iml»ìºÏÐü¸¡ÒºµÄOD6tltlֵΪ2)»ìºÏÓÚ1. 5ml ÀëÐĹÜÖУ¬ÖÃÓÚ¾²Òô»ìºÍÆ÷ÉÏÓÚ37¶È¡¢pH6. 5µÄÌõ¼þÏ·õÓý1Сʱ¡£È¥³ý·õÓýÌåϵÖÐδ½áºÏµÄϸ¾úÔ­ÉúÖÊÌ彫·õÓý²úÎï(½«ÈÝÆ÷ÄÚµÄËùÓÐÎïÖʼÇ×÷ ·õÓý²úÎï)ÖÃÓÚÀëÐĹÜÖУ¬300gÀëÐÄ2·ÖÖÓ£¬ÎüÈ¥ÉϲãÒºÌ壬ÔÙÒÔÏàͬ·½Ê½ÀëÐÄ2´Î¡£·ÖÀ븴ºÏÎïÈ¥³ý·õÓýÌåϵÖÐδ½áºÏµÄϸ¾úÔ­ÉúÖÊÌåºó£¬ÓÃÁ÷ʽϸ°ûÒǽøÐÐ·Ö Ñ¡¡£ÓÃFACSAria II (Becton Dickinson)ͨ¹ýÂÌɫӫ¹âµ°°×½øÐзÖÑ¡£¬ÊÕ¼¯·¢ÂÌɫӫ¹âµÄ H1299-tet on_PAD4ϸ°ûÓëϸ¾úÔ­ÉúÖÊÌåµÄ¸´ºÏÎï¡£»ñµÃ¿¹ÌåÐòÁн«·ÖÑ¡³öµÄ¸´ºÏÎïÓÃEasyPure Plasmid MiniPre Kit(Transgen) °´ÕÕÊÔ¼ÁºÐµÄ²Ù×÷²½ÖèÌáÈ¡±í´ï¿¹ÌåµÄÖÊÁ££¬½«ÌáÈ¡µÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§ ¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£´ÓÑôÐÔ ×ª»¯×ÓÖÐÌáÈ¡ÖÊÁ££¬½øÐвâÐò£¬½á¹ûµÃµ½SEQ ID NO :1ËùʾµÄÄ¿µÄ¿¹ÌåµÄ±àÂë»ùÒòÐòÁУ¬Ëµ Ã÷±¾·¢Ã÷·½·¨Äܹ»É¸Ñ¡µÃµ½ÕýÈ·µÄ¿¹Ìå¡£ÔÙͨ¹ý»ùÒò¹¤³Ì±í´ïºÍ´¿»¯µÃµ½Ä¿µÄ¿¹Ì塣ͳ¼Æ¸»¼¯Ð§Âʽ«·ÖÑ¡³öµÄ¸´ºÏÎïÓÃEasyPure Plasmid MiniPre Kit(Transgen) °´ÕÕÊÔ¼ÁºÐµÄ²Ù×÷²½ÖèÌáÈ¡±í´ï¿¹ÌåµÄÖÊÁ££¬½«ÌáÈ¡µÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§ ¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Ëæ»úÌô È¡48¸öת»¯×Ó£¬²ÉÓþúÂäPCR¼ø¶¨¸»¼¯ºóµÄM18´¿¶È£¬ÔÙͳ¼Æ¸»¼¯Ð§ÂÊ¡£¸»¼¯Ð§ÂʵļÆËã ¹«Ê½¸»¼¯ºóµÄM18´¿¶È/¸»¼¯Ç°µÄM18´¿¶È¡£¼ø¶¨ÒýÎïÐòÁÐ(M18ÌØÒìÒýÎï)ÈçÏÂ5¡¯ -ATATGCTAGCGATATTCAGATGACACAGACT-3¡¯ £»5 ¡¯ -GCGTTTGCCATCTTTTCATAATCAAAATCACC-3¡¯¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûȡƽ¾ùÊý¡£½á¹ûÈçͼ5Ëùʾ¡£µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔ­ÉúÖÊÌåµÄ´¿¶ÈΪ 0. ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ2%£¬Á÷ʽ·ÖÑ¡µÄ¸»¼¯Ð§ÂÊΪ20±¶¡£µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ ÒºÖÐչʾM18ϸ¾úÔ­ÉúÖÊÌåµÄ´¿¶ÈΪ5%ʱ£¬¸»¼¯ºóµÄM18´¿¶ÈΪ65.6%£¬Á÷ʽ·ÖÑ¡µÄ¸»¼¯ ЧÂÊΪ13±¶¡£µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ37¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ0. 5hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£
µ±·õÓýζÈΪ30¶È¡¢·õÓýʱ¼äΪ2hʱ£¬½á¹ûÓëͼ5Ëùʾ½á¹ûÎÞÏÔÖø²îÒì¡£×ÛºÏʵÑé(Ò»)ºÍ(¶þ)£¬½á¹û±íÃ÷£¬µ±ÓÃÓÚʵÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔ­ ÉúÖÊÌåÊýĿռËùÓÐÔ­ÉúÖÊÌåÊýÄ¿µÄ0. 1 %ʱ£¬ÌÔÑ¡±íÏÖ³ö¸üºÃµÄ¸»¼¯Ð§ÂÊ£¬Îª64±¶¡£µ±ÓÃÓÚ ÊµÑéµÄ»ìºÏÐü¸¡ÒºÖÐչʾM18ϸ¾úÔ­ÉúÖÊÌåÊýĿռËùÓÐÔ­ÉúÖÊÌåÊýÄ¿µÄ5%ʱ£¬Á÷ʽ·ÖÑ¡ ÓµÓбÈÌÔÑ¡¸üÓÅÒìµÄ¸»¼¯Ð§ÂÊ£¬Á÷ʽ·ÖÑ¡µÄ¸»¼¯Ð§ÂÊΪ13±¶£¬ÌÔÑ¡µÄ¸»¼¯Ð§ÂÊΪ5±¶¡£ÌÔÑ¡±ÈÁ÷ʽ·ÖÑ¡¸üÈÝÒײÙ×÷£¬²»ÐèÒª½øÐи´ÔÓµÄÁ÷ʽ·ÖÑ¡£¬²¢ÇÒÄܹ»»ØÊÕ¸ü¶àµÄ ±àÂ뿹Ìå»ùÒòµÄÖÊÁ££¬²»ÐèÒª·ÖÑ¡ºóPCR»ØÊ׿¹Ìå»ùÒò£¬¿ÉÒÔÖ±½Óµçת»¯Ï¸¾ú»ØÊÕÀ©ÔöÖÊ Á£¡£µ±ÌØÒ쿹Ìå±ÈÀý´ïµ½Ò»¶¨ÖµÊ±£¬Á÷ʽ¸üÈÝÒ×ͨ¹ýÇ׺ÍÁ¦µÄÇ¿Èõ½«¸ßÇ׺ÍÁ¦µÄ¿¹ÌåѸËÙ µÄɸѡ¸»¼¯³öÀ´¡£(Èý)ÌÔÑ¡·¨ºÍÁ÷ʽ·ÖÑ¡·¨½áºÏ½«Õ¹Ê¾26-10¿¹ÌåµÄϸ¾úÔ­ÉúÖÊÌåµÄÐü¸¡ÒºÓëչʾM18µÄϸ¾úÔ­ÉúÖÊÌåµÄÐü¸¡Òº »ìºÏ£¬µÃµ½»ìºÏÐü¸¡Òº£¬Ê¹»ìºÏÐü¸¡ÒºÖÐչʾM18µÄϸ¾úÔ­ÉúÖÊÌåÓëչʾ26-10¿¹ÌåµÄϸ¾ú Ô­ÉúÖÊÌåµÄÊýÄ¿±ÈΪ1 1000»ò1 104£¬È»ºó½«»ìºÏÐü¸¡Òº·Ö±ð½øÐÐÈçÏÂɸѡ¡£(1) Ò»ÂÖÌÔÑ¡ºÍÒ»ÂÖÁ÷ʽ·ÖÑ¡²½Öè1 °´ÕÕʵÑé(Ò»)ÖÐËùÊö·½·¨½øÐÐÌÔѡɸÑ¡£¬´Óɸѡ²úÎïÖлØÊÕ±í´ï¿¹ÌåµÄ ÖÊÁ££¬½«»ØÊյıí´ï¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿ ²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Í³¼Æ¸»¼¯Ð§ÂÊ¡£²½Öè2 ½«²½Öè1µÃµ½µÄÑôÐÔת»¯×ÓÖÆ³Éϸ¾úÔ­ÉúÖÊÌ壬ÔÙ°´ÕÕʵÑé(¶þ)ÖÐËùÊö ·½·¨½øÐÐÁ÷ʽ·ÖÑ¡¡£½«·ÖÑ¡µÃµ½µÄ¸´ºÏÎï°´ÕÕʵÑé(¶þ)ÖÐËùÊö·½·¨½øÐи»¼¯Ð§ÂÊͳ¼Æ¡£(2) ¶þÂÖÌÔÑ¡ºÍÒ»ÂÖÁ÷ʽ·ÖÑ¡²½Öè1 °´ÕÕʵÑé(Ò»)ÖÐËùÊö·½·¨½øÐÐÌÔѡɸÑ¡£¬´Óɸѡ²úÎïÖлØÊÕ±í´ï¿¹ÌåµÄ ÖÊÁ££¬½«»ØÊյıí´ï¿¹ÌåµÄÖÊÁ£µçתÓÚE. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿ ²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ùÉÏɸѡת»¯×Ó¡£Í³¼Æ¸»¼¯Ð§ÂÊ¡£²½Öè2:½«²½Öè1µÃµ½µÄÑôÐÔת»¯×ÓÖÆ³Éϸ¾úÔ­ÉúÖÊÌ壬°´ÕÕʵÑé(Ò»)ÖÐËùÊö ·½·¨½øÐÐÌÔѡɸÑ¡£¬´Óɸѡ²úÎïÖлØÊÕ±í´ï¿¹ÌåµÄÖÊÁ££¬½«»ØÊյıí´ï¿¹ÌåµÄÖÊÁ£µçתÓÚ E. coli Jude-Iµç»¯Ñ§¸ÐÊÜ̬ϸ°û£¬½«×ª»¯µÄϸ¾úÍ¿²¼ÓÚº¬ÓÐÂÈÃ¹ËØµÄLB¹ÌÌåÑ¡ÔñÅàÑø»ù ÉÏɸѡת»¯×Ó¡£Í³¼Æ¸»¼¯Ð§ÂÊ¡£²½Öè3 ½«²½Öè2µÃµ½µÄÑôÐÔת»¯×ÓÖÆ³Éϸ¾úÔ­ÉúÖÊÌ壬ÔÙ°´ÕÕʵÑé(¶þ)ÖÐËùÊö ·½·¨½øÐÐÁ÷ʽ·ÖÑ¡¡£½«·ÖÑ¡µÃµ½µÄ¸´ºÏÎï°´ÕÕʵÑé(¶þ)ÖÐËùÊö·½·¨½øÐи»¼¯Ð§ÂÊͳ¼Æ¡£ÊµÑéÉè3´ÎÖØ¸´£¬½á¹ûÈçͼ6Ëùʾ¡£½á¹û±íÃ÷£¬µ±ÑùÆ·ÖÐչʾM18µÄϸ¾úÔ­ÉúÖÊÌåµÄ´¿¶ÈΪ0. ʱ£¬Í¨¹ýÒ»ÂÖÌÔѡɸ Ñ¡£¬M18¿¹ÌåµÄ´¿¶ÈΪ5. 1 %£¬¸»¼¯Ð§ÂÊΪ51±¶£»È»ºóͨ¹ýÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬M18¿¹ÌåµÄ´¿¶È ÄÜ´ïµ½65. 6% £»¡ªÂÖÌÔÑ¡¼ÓÉÏÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬×ܹ²¸»¼¯ÁË 656±¶£¬´ïµ½ÁËÃ÷ÏԵĸ»¼¯Ð§¹û¡£ µ±ÑùÆ·ÖÐչʾM18ϸ¾úÔ­ÉúÖÊÌåµÄ´¿¶ÈΪ0.01%ʱ£¬Á½ÂÖÌÔѡɸѡºó£¬M18¿¹ÌåµÄ´¿¶ÈΪ 6. 25%£¬¸»¼¯Ð§ÂÊΪ625±¶£»¸»¼¯²úÎï½Ó×ÅÔÙ½øÐÐÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬Ôò¸»¼¯²úÎïÖÐM18´¿¶ÈΪ 72.9%£¬Í¨¹ýÁ½ÂÖÌÔÑ¡ºÍÒ»ÂÖÁ÷ʽ·ÖÑ¡£¬×ܹ²»ñµÃÁË > 7200±¶µÄ¸»¼¯Ð§¹û¡£´Ë½á¹û³ä·ÖµÄ ˵Ã÷Á˱¾·¢Ã÷·½·¨Äܹ»ÓÐЧµØÉ¸Ñ¡ÌØÒìʶ±ðÈËϸ°û±íÃæ¿¹Ô­µÄ¿¹Ìå¡£±¾·¢Ã÷²ÉÓÃÁËÁ½²½·¨µÄ²ßÂÔÀ´¸»¼¯Ï¸¾úÔ­ÉúÖÊÌ壬Ëü½áºÏÁËÌÔÑ¡ºÍÁ÷ʽ·ÖÑ¡µÄÓÅ µã£¬Í¬Ê±ÓÖÃÖ²¹ÁËÏ໥µÄȱµã£¬¿É´ó´óÌá¸ßɸѡЧÂÊ¡£µ±ÌØÒ쿹ÌåŨ¶È 1000ʱ£¬²ÉÓÃ
17ÌÔÑ¡À´¸»¼¯ÒÔÔö¼ÓÌØÒ쿹ÌåµÄ±ÈÀý¡£È»ºóÀûÓÃÁ÷ʽµÄ¶¨Á¿·ÖÑ¡ÄÜÁ¦£¬½«¾ßÓиü¸ßÇ׺ÍÁ¦µÄ ¿¹Ì帻¼¯³öÀ´¡£
ȨÀûÒªÇó
Ò»ÖÖɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»2)½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔ­ÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔ­ÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ÓÚËùÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔ­ÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔµÄÏ໥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔ­ÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ½«ËùÊö½áºÏÎï´Ó·õÓýÌåϵÖзÖÀë³öÀ´£»4)´Ó²½Öè3)µÃµ½µÄ½áºÏÎïÖзÖÀëµÃµ½ÓëչʾÓÚÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ÌØÒìÐÔ½áºÏµÄÄ¿µÄµ°°×»òÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£
2.¸ù¾ÝȨÀûÒªÇó1ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Ëù Êö·õÓýÌåϵµÄPHֵΪ5. 0-7. 5¡£
3.¸ù¾ÝȨÀûÒªÇó1ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þ°üÀ¨Ëù Êö·õÓýÌåϵµÄ PH ֵΪ 5. 0,5. 3,5. 5,5. 8,6. 0,6. 3,6. 5,6. 8,7. 0£¬7. 3 »ò 7. 5¡£
4.¸ù¾ÝȨÀûÒªÇó1-3ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬²½Öè3)ÖУ¬ËùÊö·õÓýµÄÌõ¼þÊÇ Î¶ÈΪ30-37¡ãCºÍʱ¼äΪ0. 5-2Сʱ£»ËùÊöζȾßÌåΪ30¡ãC»ò37¡ãC£¬ËùÊöʱ¼ä¾ßÌåΪ0. 5С ʱ»ò1Сʱ»ò2Сʱ¡£
5.¸ù¾ÝȨÀûÒªÇó1-4ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬²½Öè3)ÖУ¬½«ËùÊö½áºÏÎï´Ó·õÓý ÌåϵÖзÖÀë³öÀ´µÄ²½ÖèÊÇ£¬Ê×ÏÈʹÓÃÆ½°åÌÔÑ¡·¨É¸Ñ¡£¬È»ºóʹÓÃÁ÷ʽ·ÖÑ¡·¨·ÖÑ¡¡£
6.¸ù¾ÝȨÀûÒªÇó5ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬Ê¹ÓÃÁ÷ʽ·ÖÑ¡·¨µÄ²½ÖèΪÊ×ÏÈ´ÓËùÊö·õ ÓýÌåϵÖÐÈ¥³ýδͬËùÊöÕæºËϸ°ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔ­ÉúÖÊÌ壬ÔÙͨ¹ýÁ÷ʽϸ°ûÒÇɸ Ñ¡£¬ÊÕ¼¯ËùÊöÕæºËϸ°ûÓëÔ­ÉúÖÊÌå·¢ÉúÌØÒìÐÔ½áºÏµÄ½áºÏÎï¡£
7.¸ù¾ÝȨÀûÒªÇó6ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ´ÓËùÊö·õÓýÌåϵÖÐÈ¥³ýδͬËùÊöÕæºËϸ °ûÐγÉÌØÒìÐÔ½áºÏÎïµÄϸ¾úÔ­ÉúÖÊÌåµÄ²½ÖèΪ½«ËùÊöµÄ·õÓýÌåϵ³£ÎÂ300gÀëÐÄ1. 5-3·Ö ÖÓºó£¬ÊÕ¼¯³Áµí£¬ÆúÈ¥ÉÏÇå¡£
8.¸ù¾ÝȨÀûÒªÇó1-7ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬²½Öè1)ÖУ¬ËùÊö½«Ä¿±êµ°°×չʾÓÚÕæºËϸ°ûµÄϸ°ûĤ±íÃæÊÇÓɰüÀ¨Èçϲ½ÖèµÄ·½·¨ ÖÆ±¸µÃµ½µÄ½«º¬ÓÐËùÊöÄ¿±êµ°°×±àÂë»ùÒòµÄÖØ×é±í´ïÔØÌåתÈëËùÊöÕæºËϸ°ûÖУ¬µÃµ½ÖØ ×éÕæºËϸ°û£¬ÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬µÃµ½ËùÊö±íÃæÕ¹Ê¾ÓÐÄ¿±ê µ°°×µÄÕæºËϸ°û£»²½Öè2)ÖУ¬½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæµÄ·½·¨°üÀ¨Èç ϲ½Ö轫´ýɸѡµ°°×µÄ±àÂë»ùÒò²åÈëϸ¾ú±í´ïÔØÌåÖУ¬µÃµ½±í´ïËùÊö´ýɸѡµ°°×µÄÖØ×é ÔØÌ壬½«ËùÊö±í´ï´ýɸѡµ°°×µÄÖØ×éÔØÌåתÈëËÞÖ÷ϸ¾ú£¬µÃµ½ÖØ×éϸ¾ú£¬ÅàÑøËùÊöÖØ×éϸ¾ú ²¢ÓÕµ¼ËùÊöÖØ×éÔØÌåµÄ±í´ï£¬ÔÙÌáÈ¡ÖØ×éϸ¾úµÄÔ­ÉúÖÊÌ壬µÃµ½ËùÊö±íÃæÕ¹Ê¾Óдýɸѡµ° °×µÄϸ¾úÔ­ÉúÖÊÌå¡£
9.¸ù¾ÝȨÀûÒªÇó1-8ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöº¬ÓÐËùÊöÄ¿±êµ°°×µÄ±àÂë »ùÒòµÄÖØ×éÔØÌåÊÇÊÜËÄ»·Ëص÷¿ØµÄÖØ×éÔØÌ壻ËùÊöÅàÑø¸ÃÖØ×éÕæºËϸ°û²¢ÓÕµ¼ËùÊöÖØ×éÔØ ÌåµÄ±í´ïµÄ·½·¨Îª½«²åÈëÍâÔ´»ùÒòºóµÄÕæºË±í´ïÔØÌåתÈëËùÊöÕæºËϸ°û£¬²¢ÓÃËÄ»·ËØÓÕµ¼ËùÊöÕæºËϸ°û±í´ïÄ¿±êµ°°×¡£
10.¸ù¾ÝȨÀûÒªÇó1-9ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöËÞÖ÷ϸ¾úÖл¹×ªÈëÓÃÓÚͨ¹ýÓ«¹â ÐźÅɸѡԭÉúÖÊÌåµÄÓ«¹âµ°°×±í´ïÔØÌå¡£ËùÊöÓ«¹âµ°°×±í´ïÔØÌå¿ÉÒÔÊÇÔÚϸ¾úÖбí´ïÈκΠÑÕɫӫ¹âµ°°×ÖʵÄÔØÌ壬ÓÅѡΪPBAD30-KmR-GFPmut2¡£
11.¸ù¾ÝȨÀûÒªÇó1-10ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöÄ¿±êµ°°×µÄ±àÂë»ùÒò ÊÇÈËÔ´»¯µÄ£»ËùÊöÕæºËϸ°ûÊÇÈË·ÇСϸ°û·Î°©Ï¸°ûÖêH1299 £»ËùÊöÕæºË±í´ïÔØÌåÎªÕæºËϸ °ûĤ±íÃæÕ¹Ê¾ÔØÌ壻ËùÊöÕæºËϸ°ûĤ±íÃæÕ¹Ê¾ÔØÌåÊǺËÜÕËáÐòÁÐÊÇSEQ ID 6ËùʾµÄÔØÌå pUHD10-3-display¡£
12.¸ù¾ÝȨÀûÒªÇó1-11ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöËÞÖ÷ϸ¾úΪ´ó³¦¸Ë¾ú£¬ÓŠѡΪ E.coli Jude-I0
13.¸ù¾ÝȨÀûÒªÇó1-12ÖÐÈÎÒ»ËùÊöµÄ·½·¨£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊö²½Öè4)ÖУ¬ËùÊö´Ó½áºÏÎï ÖзÖÀëµÃµ½Ä¿µÄµ°°×»òÄ¿µÄµ°°×µÄ±àÂë»ùÒòµÄ·½·¨°üÀ¨Èçϲ½Öè´ÓËùÊö½áºÏÎïÖÐÌáÈ¡Ëù Êö±í´ïÄ¿µÄµ°°×µÄÖØ×éÔØÌ壬¶ÔÖØ×éÔØÌå½øÐвâÐò£¬µÃµ½ËùÊöÄ¿µÄµ°°×µÄ±àÂë»ùÒò¡£
14.Ò»ÖÖ¸¨Öú¼ø¶¨µ°°×ÊÇ·ñÓëÄ¿±êµ°°×½áºÏµÄ·½·¨£¬°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»2)½«´ý¼ø¶¨µ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдý¼ø¶¨ µ°°×µÄϸ¾úÔ­ÉúÖÊÌå¿â£»3)½«²½Öè1)µÃµ½µÄÕæºËϸ°ûÓë²½Öè2)µÃµ½µÄϸ¾úÔ­ÉúÖÊÌå¿â¹²Í¬·õÓý£¬Ê¹Õ¹Ê¾ÓÚËù ÊöÕæºËϸ°û±íÃæµÄÄ¿±êµ°°×ºÍչʾÓÚËùÊöϸ¾úÔ­ÉúÖÊÌå±íÃæµÄµ°°×Ö®¼ä·¢ÉúÌØÒìÐÔµÄÏà »¥Åä¶Ô£¬µÃµ½ËùÊöÕæºËϸ°ûÓëËùÊöϸ¾úÔ­ÉúÖÊÌåµÄÌØÒìÐÔ½áºÏÎ¼ì²â·õÓýµÄÌåϵÖÐÊÇ·ñ º¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÈôº¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×ÓëËùÊöÄ¿±êµ°°×½á ºÏ£¬Èô²»º¬ÓÐËùÊöÌØÒìÐÔ½áºÏÎÔòËùÊö´ý¼ø¶¨µ°°×²»ÓëËùÊöÄ¿±êµ°°×½áºÏ¡£
15.Ò»ÖÖÓÃÓÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×µÄÊÔ¼ÁºÐ£¬ÓÉÕæºËϸ°û¡¢ÕæºËϸ°û±í´ïÔØ Ìå¡¢ÓÃÓÚÖÆ±¸Ô­ÉúÖÊÌåµÄϸ¾ú¡¢Ô­ÉúÖÊÌåÕ¹Ê¾ÔØÌå¡¢ÔÚÔ­ÉúÖÊÌåÖбí´ïÓ«¹âµ°°×ÒÔ±ãÓÚɸѡ µÄÔØÌå×é³É¡£
16.¸ù¾ÝȨÀûÒªÇó15ËùÊöµÄÊÔ¼ÁºÐ£¬ÆäÌØÕ÷ÔÚÓÚ£¬ËùÊöÕæºËϸ°ûΪÈË·ÇСϸ°û·Î°© ϸ°ûÖêH1299 £»ËùÊöÕæºËϸ°û±í´ïÔØÌåΪpUHDlO-3-display £»ËùÊöϸ¾úΪ´ó³¦¸Ë¾ú¾úÖê Jude-I £»ËùÊö±í´ïÓ«¹âµ°°×µÄÔØÌåΪpBAD30-KmR-GFPmut2¡£
17.ȨÀûÒªÇó15-16ËùÊöÊÔ¼ÁºÐÔÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×ÖеÄÓ¦Óá£
18.ϸ¾úÔ­ÉúÖÊÌåչʾ·½·¨ÔÚɸѡÓëÄ¿±êµ°°×½áºÏµÄÄ¿µÄµ°°×ÖеÄÓ¦Óá£
È«ÎÄÕªÒª
±¾·¢Ã÷¹«¿ªÁËÒ»ÖÖɸѡ¿¹ÌåµÄ·½·¨¡£¸Ã·½·¨°üÀ¨Èçϲ½Öè1)½«Ä¿±êµ°°×չʾÓÚÀëÌåÕæºËϸ°ûµÄϸ°ûĤ±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾ÓÐÄ¿±êµ°°×µÄÕæºËϸ°û£»2)½«´ýɸѡµ°°×¿âÖеĸ÷µ°°×·Ö±ðչʾÓÚϸ¾úÔ­ÉúÖÊÌå±íÃæ£¬µÃµ½±íÃæÕ¹Ê¾Óдýɸѡµ°°×µÄϸ¾úÔ­ÉúÖÊÌå¿â¡£±¾·¢Ã÷ÌṩÁËÀûÓÃAPExչʾ¼¼ÊõÓ¦ÓÃÓÚÒÔÍêÕûµÄÈËϸ°ûΪ¿¹Ô­É¸Ñ¡ÌØÒìʶ±ðÈËϸ°û±íÃæ¿¹Ô­µÄ¿¹ÌåµÄÒ»ÖÖɸѡ·½·¨¡£APExϸ¾úչʾϵͳӵÓÐÓëÊɾúÌåչʾϵͳÏ൱´óСµÄ¿¹Ìå¿â(¡Ý109)£¬²¢ÇÒ¾ßÓÐչʾÍêÕûµÄIgG¿¹ÌåµÄÄÜÁ¦¡£´Ë·½·¨µÄ½¨Á¢£¬ÓÐÖúÓÚɸѡ¸ü¶àʶ±ðϸ°û±íÃæ·Ö×Ó±ê¼ÇµÄ¿¹Ì壬¶Ô¼²²¡Õï¶ÏºÍÖÎÁƶ¼½«Æðµ½¾Þ´óµÄÍÆ¶¯×÷Óá£
Îĵµ±àºÅG01N33/53GK101948534SQ20101025736
¹«¿ªÈÕ2011Äê1ÔÂ19ÈÕ ÉêÇëÈÕÆÚ2010Äê8ÔÂ19ÈÕ ÓÅÏÈȨÈÕ2010Äê8ÔÂ19ÈÕ
·¢Ã÷Õߺ¼º£Ó¢, Çñ¿¡¿µ ÉêÇëÈË:Öйú¿ÆÑ§ÔºÉúÎïÎïÀíÑо¿Ëù

  • רÀûÃû³Æ£ºÓÃÓÚÎÞÏßÍøÂç»ìºÏ¶¨Î»µÄ·½·¨ºÍÉ豸µÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Éæ¼°Î»ÖÃÈ·¶¨ÏµÍ³£¬ÇÒ¸üÌØ¶¨µØËµ£¬É漰ʹÓÃÎÞÏßͨÐÅÐźŵĻìºÏ¶¨Î»¡£ ±³¾°¼¼Êõ£ºÎªÔÚÎÞÏß·äÎÑÊ½ÍøÂç(ÀýÈç·äÎÑʽµç»°ÍøÂç)ÖÐÖ´ÐÐλÖö¨Î»£¬Èô¸É·½·¨»ùÓÚʹÓÃÔÚÈô¸É»ùÕ¾ÖеÄÿһ¸öÓëÒ»
  • רÀûÃû³Æ£ºÒ»ÖÖ¸ß×迹¿íƵ´ø¸ßµçѹ·ÖѹÆ÷µÄÉè¼Æ·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Éæ¼°µçÁ¦ÏµÍ³µçÁ¦Æ÷¼þÁìÓò£¬¾ßÌåÉæ¼°Ò»ÖÖ¸ß×迹¿íƵ´ø¸ßµçѹ·ÖѹÆ÷µÄÉè¼Æ·½·¨¡£ ±³¾°¼¼Êõ£º1¡¢ÎÊÌâµÄÌá³ö µçÁ¦ÐÐÒµÖг£³£ÐèÒª²âÁ¿ÉÏÍò·üÌØµÄ¸ßµçѹ¡£×èÈÝ·ÖѹÆ÷ÊÇÒ»ÖÖÓÃÓڸߵçѹ²âÁ¿ µÄ
  • רÀûÃû³Æ£ºÆøÆ¿±¬ÆÆÊÔÑéÓõõÔË×°ÖõÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾ÊµÓÃÐÂÐÍÉæ¼°ÈÝÆ÷ÁìÓò£¬ÓÈÆäÉæ¼°ÆøÆ¿±¬ÆÆÊÔÑéÓõõÔË×°Öᣠ±³¾°¼¼Êõ£ºÏÖÓм¼ÊõÖУ¬×°¸ßÑ¹ÆøÌåµÄÆøÆ¿ÐèÒª²ÉÓñ¬ÆÆÊÔÑéÀ´¼ì²âÆäÄ͸ßѹµÄÐÔÄÜ¡£ÔÚ ±¬ÆÆÊÔÑéÖУ¬ÐèÒªÓõ½µõÔË×°Öᣳ£ÓõĵõÔË×°ÖðüÀ¨ÐÐ
  • רÀûÃû³Æ£º»ùÓÚÓ«¹âÊÙÃü·¨µÄË®ÌåÈܽâÑõŨ¶È¼ì²âϵͳ¼°·½·¨¼¼ÊõÁìÓò£º±¾·¢Ã÷Éæ¼°»·¾³¼à²â¼¼ÊõÁìÓò£¬¾ßÌåÉæ¼°Ò»ÖÖ»ùÓÚÓ«¹âÊÙÃü·¨µÄË®ÌåÈܽâÑõŨ¶È ¼ì²âϵͳ¼°·½·¨¡£±³¾°¼¼Êõ£ºÓ«¹â·¨ÈܽâÑõ¼ì²â¼¼ÊõÓÉÓÚ¾ßÓо«¶È¸ß£¬ÏìÓ¦¿ì£¬²»ÏûºÄÑõµÈÓŵ㣬¿ÉʵÏÖË®ÌåÈÜ ½âÑõ
  • רÀûÃû³Æ£ºÑ¹Á¦±í¼ì¶¨×Ô¶¯ÔìѹװÖõÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£º±¾ÊµÓÃÐÂÐÍÉæ¼°Ò»ÖÖѹÁ¦±í¼ì¶¨×°Ö㬾ßÌåµÄ½²ÊÇÒ»ÖÖѹÁ¦±í¼ì¶¨×Ô¶¯ÔìѹװÖᣱ³¾°¼¼Êõ£ºÄ¿Ç°£¬´ó²¿·ÖѹÁ¦±í¼ì¶¨×°Öõ͝Á¦ÏµÍ³¾ù²ÉÓô«Í³µÄÊÖ¶¯²Ù×÷ѹÁ¦¸Ë£¬Í¨¹ý»îÈû±ÃµÄÍù¸´Ô˶¯À´Íê³É¶ÔѹÁ¦±í¼ì¶¨×°ÖÃ
  • רÀûÃû³Æ£ºÌýÕïÆ÷²âÁ¿Ê½À®°È¾ÛÒôÐÍÒôƵÉúÃü̽²âÒǵÄÖÆ×÷·½·¨¼¼ÊõÁìÓò£ºÌýÕïÆ÷²âÁ¿Ê½À®°È¾ÛÒôÐÍÒôƵÉúÃü̽²âÒÇ£¬ÊÇÀûÓÃÀ®°ÈÐξÛÒôÆ÷¿ÉÒÔ¾ÛÒôµÄÌØµã£¬½«³öÊÜÀ§ÈËȺ·¢³öµÄÉùÒôͨ¹ýÀ®°ÈÐξÛÒôÆ÷¡¢ÌýÕïÆ÷Õñ¶¯Ä¤ºÍÌýÕïÆ÷´«µ½È˶úÖУ¬ ¿ÉÒÔ¼°Ê±Ì½²â³öÊÜÀ§ÈËȺ£¬¸ÃÒÇ
ɽ¶«ÑÇÐÇÓÎÏ·¹ÙÍø»ú´²ÓÐÏÞ¹«Ë¾
È«¹ú·þÎñÈÈÏߣº13062023238
µç»°£º13062023238
µØÖ·£ºëøÖÝÊÐÁúȪ¹¤ÒµÔ°68ºÅ
¹Ø¼ü´Ê£ºÏ³´²£¬Êý¿ØÏ³´²£¬ÁúÃÅϳ´²
¹«Ë¾¶þάÂë
Copyright 2010-2024 °æÈ¨ËùÓÐ All rights reserved ³ICP±¸19044495ºÅ-12
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿